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Abstract 
Background - In Hong Kong, approximately one in ten adults have type 2 diabetes. 
Prostacyclin synthase gene (PTGIS) is located on chromosome 20q, which is one of 
the type 2 diabetes susceptibility loci. Its enzymatic product, prostacyclin, activates a 
type 2 diabetes susceptibility gene, peroxisome proliferator-activated receptor 
(PPAR)-5 which is a powerful transcription factor regulating glucose and lipid 
metabolism. 
Aim - M y thesis aimed at investigating whether the polymorphisms in PTGIS and 
PPAR5 genes (PPARD) as well as their interactions are associated with the risk of type 
2 diabetes and the related metabolic traits. The functional significance of a PTGIS 
SNP rs508757 was investigated as well. 
Method - Ten single nucleotide polymorphisms (SNPs) in PTGIS and two SNPs in 
PPARD were genotyped in a Hong Kong Chinese population of 630 type 2 diabetic 
patients and 595 non-diabetic control subjects. W e tested these SNPs for association 
with type 2 diabetes and related traits including anthropometry, glucose and lipid 
levels. The function of PTGIS rs508757 on transcriptional activity was assessed by 
luciferase reporter gene assay. 
Result - The eight successfully genotyped SNPs did not associate with type 2 
III 
diabetes. Nevertheless, A A homozygotes of rs2016520 of PPARD was associated with 
a higher LDL-C level in control subjects {p = 0.044). In addition, PTGIS rs508757 and 
PPARD rs2016520 had a significant epistatic effect on blood glucose levels {p <0.05). 
Further in vitro luciferase assay results indicated that PTGIS rs508757 resides in a 
regulatory region of the gene. Specifically, the A but not the G allele of rs508757 
enhanced transcriptional activity of the SV40 promoter. Transcription factor binding 
site prediction identified PAX4 and c-Ets-1 as likely candidates for regulating the 
expression of PTGIS and PPARD. 
Conclusion - In this Hong Kong Chinese cohort, the eight genotyped SNPs in PTGIS 
and PPARD do not associate with type 2 diabetes. PPARD rs2016520 is associated 
with LDL-C level in control subjects. Moreover, PTGIS rs508757 and PPARD 
rs2016520 interact to modify blood glucose level. Consistent with the effects observed 
in epidemiological studies, PTGIS rs508757 was found to be involved in 
transcriptional regulation. Further studies on the physiological roles of these genes 
will elucidate the mechanisms underlying their effects on metabolic traits relevant to 
type 2 diabetes. 
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Chapter 1: Introduction 
1.1 Overview on type 2 diabetes 
1.1.1 Definition of diabetes 
Diabetes mellitus is a metabolic disorder caused by inherited and/or acquired 
deficiency in production of insulin by the pancreas or by the ineffectiveness of the 
insulin produced (known as insulin resistance). It is characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism. The 
effects of diabetes mellitus include long-term damage, dysfunction and failure of 
various organs (WHO, 1999). Two main forms of the disease can be distinguished. 
Type 1 diabetes mellitus, known as insulin-dependent diabetes, is caused by 
autoimmune destruction of pancreatic (3-cells and leads to failure in synthesis and 
secretion of insulin. Type 2 diabetes accounts for most individuals with 
non-autoimmune forms of diabetes. It results from a combination of insulin 
resistance and p-cell dysfunction which leads to inadequate insulin secretion 
(Zimmet et al., 2001). Altogether, 10-15% of diabetic individuals have type 1 
diabetes, including latent onset autoimmune diabetes of the adult (LADA) (Pozzilli 
et al., 2001) and 90% have type 2 diabetes (Zimmet et al., 2001). Diabetes resulting 
from surgery or illness only accounts for 1 -5% of all cases. 
1 
1.1.2 Diagnostic criteria 
As defined by the World Health Organization (WHO) criteria, diabetes mellitus is 
diagnosed of both fasting and 2-h (after 75g of glucose load) glucose levels (WHO, 
1999) (Table 1.1.1). Impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG) are the intermediate conditions between normoglycemia and diabetes. 
Individuals with IGT and IFG are at increased risk for type 2 diabetes. 
Table 1.1.1 Diagnostic criteria for diabetes mellitus and other categories of 
hyperglycemia 
Glucose concentration in venous plasma (mmol/1) 
Fasting 2-h post glucose load 
Diabetes mellitus >7.0 or >11.1 
Impaired glucose tolerance (IGT) < 7.0 and 7.8 - 11.0 
Impaired fasting glucose (IFG) 6.1-6.9 and <7.8 
Normoglycemia < 6.1 and < 7.8 
1.1.3 Prevalence and societal impact 
A diabetic epidemic has been underway since last few decades. According to the 
W H O statistics, there are over 177 million people having diabetes worldwide 
(prevalence of 2.8% in all age groups). This number is expected to increase to 366 
million by 2030 (prevalence of 4%), with the greatest increases in developing 
countries of South America, Africa and Asia (Wild et ai, 2004). Also, there are 
growing numbers of children, teenagers and adolescents getting diabetes (Sinha et 
2 
al, 2002; Cali et al, 2008), where type 2 form may occur more commonly than type 
1 diabetes (Alberti et al, 2004). 
In Hong Kong, the age-adjusted prevalence of diabetes was 8.9% in 1995 (Cockram, 
2000) which was the second highest prevalence in East Asia next to Taiwan. And the 
prevalence increases to about 10% now. According the health statistics from the 
Department of Health of Hong Kong at 2007, diabetes mellitus was the cause of 
death and accounted for over 500 deaths. This high prevalence is thought to be due 
to the affluent and westernized lifestyle of Hong Kong Chinese, resulting from rapid 
socioeconomic development over the last few decades. This is compatible with the 
thrifty genotype hypothesis, in which favorable genetic traits that facilitate energy 
storage and mobilization in times of famine are detrimental during time of plenty of 
food and energy (Neel et al., 1998). And this further interacts with the high 
prevalence of physical inactivity and overweight and obesity (18.9% and 38.4%, 
respectively) and contributes to the high prevalence of diabetes mellitus in Hong 
Kong. 
Diabetes causes economic and medical burden together with associated 
complications, which all greatly increase morbidity and mortality (Wei et al, 1998; 
Turner et al., 1998). For example, cardiovascular morbidity is two to four times 
higher in patients with type 2 diabetes than in non-diabetic subjects (Zimmet et al., 
3 
2001). Furthermore, diabetes frequently goes undiagnosed for many years as 
hyperglycemia develops gradually, but the costs for disease management arise 
several years prior to the diagnosis (Nichols et ai, 2000). 
1.1.4 Risks factors for type 2 diabetes 
Type 2 diabetes is a heterogeneous disease influenced by multiple risk factors 
(Figure 1.1.1). These risk factors are interrelated. Major risk factors are listed below. 
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Figure 1.1.1 Risk factors for developing type 2 diabetes. These risk factors are 
interrelated and also responsible for associated metabolic disorders. In addition, 
aging is also a risk factor for type 2 diabetes. (HDL-C, high-density 
lipoprotein-cholesterol) (Modified from Hansen, 2002) 
1.1.4.1 Metabolic syndrome 
Metabolic syndrome is a clustering of multiple disorders including hyperglycemia, 
4 
hypertension, dysliplidemia, low high-density lipoprotein cholesterol (HDL-C) and 
obesity (NCEP, 2001; ADA, 2007) and all these are risk factors for type 2 diabetes 
(Bakris et ai, 2008). Diabetes and hypertension frequently co-exists and lead to 
additive increases in the risk of life-threatening cardiovascular events. Hypertension 
occurs in 75% of patients with type 2 diabetes (Schutta, 2007). Barkris et al. used 
logistic regression modeling to show that glycosylated haemoglobin (HbAic), 
hypertensive drug treatment and blood glucose levels were baseline predictors of 
diabetes. This further indicates that hypertensive patients are at higher risk of 
diabetes. Obesity is another high risk factors for type 2 diabetes. Type 2 diabetes is 
usually associated with increase fat mass (Haslam et al, 2005) and goes hand in 
hand with the epidemic of obesity (Mokdad et al., 2003). Body mass index (BMI) is 
the most common measurement of obesity. For the Asian Criteria, individuals with a 
B M I greater than 23 k g W are defined as overweight while those with a B M I 
greater than 30 kg/m^ are classified as obese (Haslam et al, 2005). Among type 2 
diabetic patients, about 90% are overweight or obese, even B M I greater than 23 
kg/m^ is associated with a slightly elevated risk of diabetes. BMI of SOkg/m^ raises 
the risk up to 20-fold and further increases to 42-fold when B M I is 3 5 k g W or 
higher (Chan et al., 1994). In contrast, even mild weight loss may improve glycemic 
control and lipid profiles, yet currently available synthetic therapeutic agents are of 
5 
limited effectiveness (Yanovski et al., 2002). 
The effects of adiposity on diabetes depends on the average size of adipocyte 
(Weyer et al., 2001), glucose metabolism in adipocyte (Abel et al., 2001) and the 
localization of the fat storage (subcutaneous and visceral), especially the ectopic 
accumulation of fat in non-adipose tissues such as liver and muscle (Yki-Jarvinen, 
2005; Machann et al., 2004). 
1.1.4.2 Genetics of type 2 diabetes 
Evidence for a genetic component in type 2 diabetes comes from several sources: 
familial aggregation, study of monozygotic and dizygotic twins, monogenic form of 
type 2 diabetes and epidemiological studies. 
Familial aggregation indicates the presence of genetic component of diabetes. 
Individuals with first-degree relatives with type 2 diabetes have a higher prevalence 
than the general population. Also, fasting insulin, fasting glucose and BMI exhibited 
significant heritability (Henkin et al, 2003). The lifetime risk of developing the 
disease is 40% if one of the parents is affected and up to 70% if both parents are 
affected, which corresponds to a 3.5- and 6.1-fold increase in the odds ratio (OR) 
respectively (Meigs et al., 2000). 
Studies of monozygotic and dizygotic twins have been used to distinguish the 
6 
genetic component from the non-genetic components including environmental 
factors and lifestyle habits. In individuals older than 60 years, concordance rates for 
diabetes were 35-58% in monozygotic twins, compared with 17-20% in dizygotic 
twins. Inclusion of impaired glucose tolerance markedly increased the concordance 
in monozygotic twins to 88% (Henkin et al., 2003). 
As with many other complex traits, much information relevant to type 2 diabetes 
gained from studies of the monogenic forms, for example, maturity onset of the 
young (MODY) of diabetes. Mutations in the genes encoding hepatic nuclear factor 
la {HNFla), HNFip, HNF4a, glucokinase and insulin promoter factor 1 are all 
inherited by an autosomal dominant way in different M O D Y subtypes (Fajans et cd., 
2001). Although they might only account for 5% of diabetes, powerful 
genotype-phenotype correlations have aided gene discovery efforts, provided 
valuable insights into the machinery of glucose homeostasis and facilitated rapid 
clinical translation (Owen et al, 2007). 
Over the past 15 years, numerous epidemiological studies from linkage studies, 
positional cloning and candidate gene approaches have been successful in 
identifying the susceptibility loci and genes for type 2 diabetes (Hansen, 2002; Rich, 
2006). Recently, genome-wide association studies using single nucleotide 
polymorphisms (SNPs) of large case-control cohorts indicates further susceptibility 
7 
genes, such as TCF7L2 and SLC30A8 (Scott et al., 2007; Sladek et al., 2007). 
1.1.4.3 Environmental risk factors, lifestyle and energy imbalance 
In the neonatal stage, fetus with intra-uterine malnutrition result in too low or high 
birth weights which are associated with increased risk of diabetes later in life (Pettitt 
et al., 2001; Wei et al., 2003). During the course of life, it is widely believed that 
regular physical activity, a diet low in saturated fat and rich in fiber, non-refined 
carbohydrates, not smoking and moderate alcohol intake can all reduce the risk of 
diabetes (Fletcher et al., 2002; Hu et al., 2001). Excess calorie intake and physical 
inactivity lead to energy imbalance and eventually obesity, which are important risk 
factors for type 2 diabetes (Hu et al, 2001). Furthermore, the risk of getting diabetes 
increases with age, male gender, and previous history of gestational diabetes. (Wild 
et al., 2004; Fletcher et al, 2002). 
8 
1.1.5 Pathophysiology of type 2 diabetes 
Insulin is the major hormone in controlling blood glucose level. Any defects in 
insulin secretion and insulin action will lead to dysglycemia. Normal glucose level 
is maintained through balanced and life-long coordination of insulin and other 
glucose-regulating hormones (such as glucagon and growth hormone) in the major 
metabolic tissues including liver, skeletal muscle and adipose tissues. 
In addition to insulin signaling, tlie recently characterized endocannabinoid system 
also regulates energy balance and metabolism which are important in 
pathophysiology of type 2 diabetes. 
1.1.5.1 Insulin secretion and signaling 
1.1.5.1.1 Insulin Secretion 
Insulin is produced from the P-cells of the Islet of the Langerhans of the pancreas. 
Numerous metabolic stimuli, hormones and neural factors regulate the secretion of 
insulin, however, the main physiological determinant of insulin release is the 
elevation of glucose concentration in blood. Glucose is rapidly taken up by the 
pancreatic p-cell via the glucose transporter 2 (GLUT2), upon which it is 
phosphorylated by glucokinase, which is the rate-limiting step of P-cell glucose 
metabolism. Further degradation leads to formation of pyruvate, which is then taken 
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up in the mitochrondia in which further metabolism leads to ATP formation. ATP is 
necessary for the delivery of energy needed for the release of insulin and also 
involved in the cell membrane depolarization. The ADP/ATP ratio leads to 
activation of sulphonylurea receptor 1 (SURl) which will lead to closure of the 
adjacent potassium channel (potassium inward rectifier channels, KIR 6.2 channel). 
The closure of the potassium channels will alter the membrane potential and open 
calcium channels, which triggers the release of preformed insulin-containing 
granules (Figure 1.1.2) (Stumvoll et al., 2005). Insulin is released in a pulsatile 
manner. The first rapid phase of exocytosis lasts for 5-10 min and is followed by a 
prolonged second phase for the duration of the glucose stimulus (Del Prato et al., 
2002). 
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Figure 1.1.2 Schematic representation of normal glucose-induced insulin 
secretion. (Co-A, coenzyme A; G-6-P, glucose-6-phosphate; lAPP, islet amyloid 
polypeptide; adopted from Stumvoll et al., 2005) 
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1.1.5.1.2 Insulin signaling 
Insulin is the most potent anabolic hormone known. It promotes the synthesis and 
storage of carbohydrates, lipids and proteins, while inhibiting their degradation and 
release into the circulation. The biological effects of insulin are exerted upon 
binding to insulin receptors (IR) which are expressed abundantly in different tissues, 
especially liver, skeletal muscle and adipose tissues (Taniguchi et al., 2006). IR are 
tetrameric proteins consisting of two a- and two p-subunits that function as 
allosteric enzymes in which the a-subunit inhibits the tyrosine kinase activity of the 
P-subunit. Insulin binding to the a-subunit leads to derepression of the kinase 
activity in the p-subunit and phosphorylates insulin receptor substrate (IRS) proteins. 
They activate two main signaling pathways: phosphatidylinositol 3-kinase (PI3-K) 
pathway and ras-mitogen-activated protein kinase (MAPK) pathway. PI3-K 
activates a variety of downstream signaling cascades, leading to GLUT4 regulated 
glucose uptake and specific gene expression involved in glycogen, lipid and protein 
synthesis. The ras-MAPK pathway enhances transcriptional activity of genes and 
cooperates with the PI3-K pathway to control cell growth and differentiation (Saltiel 
etal,2m). 
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1.1.5.2 Natural history of type 2 diabetes 
Defects in both insulin secretion and action resulting from the genetic and acquired 
components are the main factors leading to the development of type 2 diabetes. 
Decreased insulin sensitivity is usually the earliest metabolic change, which leads to 
compensatory hyperinsulinemia to overcome insulin resistance and to maintain 
normal glucose homeostasis (Martin et al., 1992). However, even mild elevation in 
blood glucose level and associated glucose toxicity may lead to p-cell dysfunction, 
particularly in genetically susceptible obese individuals (Weyer et al., 1999). The 
duration of increased insulin secretion depends on the secretory capacity, mass, 
neogenesis and apoptosis rate of pancreatic p-cells (Rhodes, 2005). Thus, the 
progression from normoglycemia, IFG, IGT is a slow process which lasts for several 
years. The patient finally develops type 2 diabetes when the amount of secreted 
insulin is no longer sufficient to maintain blood glucose level together with insulin 
resistance (Figure 1.1.3). 
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Figure 1.1.3 Natural history of type 2 diabetes. As much as one fourth of 
individuals with IGT convert to diabetes during a period of 5 years (Jarrett et al., 
1984). Many common marcovascular complications (coronary heart disease, 
cerebrovascular and peripheral vascular diseases) often precede the diagnosis of 
diabetes whereas microvascular complications usually develop in a later phase of 
the disease (Haffner et al., 1990). 
1.1.5.3 Insulin resistance 
Insulin resistance is said to be present when the biological effects of insulin are less 
than expected for both glucose disposal in skeletal muscle and suppression of 
endogenous glucose production primarily in the liver (Dinneen et al., 1992). Insulin 
resistance is strongly associated with obesity and physical inactivity, and several 
mechanisms mediating this interaction have been identified. A number of circulating 
hormones, cytokines, and metabolic fuels, such as non-esterified free fatty acids 
(NEFA) originate from adipocyte and modulate insulin action. An increased fat 
storage in visceral or deep subcutaneous adipose tissues lead to increased release of 
these molecules and aggravate insulin resistance in skeletal muscle and liver (Boden, 
13 
1997). Increased lipid storage in skeletal muscle and liver can further worsen the 
resistance (Machann et al., 2004; Bajaj et ai, 2003). 
Cellular mechanisms leading to insulin resistance are summarized in figure 1.1.4. 
Inhibitory triggers such as high glucose, NEFA and inflammatory signals activate 
the deactivation pathways and suppress insulin-activated pathways. This results in 
less glucose uptake and increased lipolysis (Stumvoll et al., 2005). 
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Figure 1.1.4 Insulin signaling and insulin resistance. Insulin signaling involves 
binding of insulin to its receptor followed by a cascade of intracellular events, 
depicted as activation pathways. Negative modulation of insulin action can be 
mediated via various pathways leading to insulin resistance: various inhibitory 
triggers affect their respective signal modulators (partly via transcription factors), 
which lead through deactivating pathways (tyrosine phosphatases, serine kinases, 
lipid phosphatases and degradation pathways) to inhibitory actions on insulin 
signalling (activation pathways). (DCKp, inhibitor kB kinase p; IRS, insulin receptor 
substrate; PKC, protein kinase C; PI, phospho-inositol; PTEN, phosphatase and 
tensin homologue; PTPIB, phosphotyrosine phosphatase IB; SOCS-3, suppressor of 
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cytokine signaling 3 modified from Stumvoll et al. 2005) 
1.1.5.4 Impairment in insulin secretion 
Besides insulin resistance, the reduction of p-cell function and insulin deficiency 
develops early in the subjects with IFG and IGT and is prominent at the time of the 
diagnosis of diabetes and may further deteriorate afterwards (Kahn, 2001). The 
observation that prolonged hyperglycemia can lead to decreased insulin secretion 
gave rise to the concept of glucose toxicity. The toxic effects of glucose can be 
mediated through increased production of reactive oxygen species, down-regulation 
of glucose transporters and induction of (3-cell apoptosis (Robertson et al, 2003). 
Moreover, prolonged exposure to elevated free fatty acids (FFAs), commonly 
observed in patients with type 2 diabetes, may also lead to decreased 
glucose-stimulated insulin secretion and p-cell apoptosis. This may be due to 
oxidative stress caused by excessive fatty acids disposal through mitochondrial 
p-oxidation and accumulation of lipid-derived intracytosolic metabolites (Robertson 
e/(3/., 2004). 
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1.1.5.5 Endocannabinoid system: A new target for energy balance and 
metabolism 
Endocannabinoids are endogenous phospholipid derivatives which bind and activate 
cannabinoid receptor type 1 and type 2 (CBl and CB2 receptors) (Di Marzo, 2008). 
Recent studies have provided evidence that the endocannabinoid system (ECS) has 
very significant effects on energy balance and metabolism through the central 
control of appetite and by affecting peripheral metabolism particularly via CBl 
receptor (Despres, 2007). Chronic positive energy balance and obesity have been 
associated with an overactivation of the ECS which suggested to contributing to the 
development of abdominal obesity and type 2 diabetes. Stimulation of CBl receptor 
in the brain with endocannabinoids such as anandamide and 2-arachidonoylglycerol 
(2-AG) enhances appetite and food intake. Peripheral activation of CBl in liver and 
adipose tissue stimulates lipogenesis (Di Marzo et al, 2005). In contrast, CBl 
antagonist rimonabant has been shown to reduce body weight in preclinical studies 
(Di Marzo, 2008). 
1.1.5.6 Effects of diabetes mellitus and its complications 
Patients with diabetes mellitus may present with characteristic symptoms such as 
thirst, polyuria, blurring of vision and weight loss. In its most severe forms may lead 
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to coma and death. Often the symptoms are not severe or even absent and so chronic 
hyperglycemia causes long-term and progressive damage, dysfunction and failure of 
various organs. Common complications include cateract and retinopathy, 
nephropathy and renal failure, neuropathy with risk of foot ulcers and amputation. 
Diabetic patients are also at risk of cardiovascular and cerebovascular diseases 
(WHO, 1999). 
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1.2 Biology of prostacyclin synthase (PTGIS) 
1.2.1 Molecular information of PTGIS 
Prostacyclin (PGI2) was discovered about three decades ago by Vane's group and its 
structure was deduced in the same year (Bunting et al, 1976; Whittaker et al., 1976). 
It was subsequently shown that it is converted from the prostaglandin endoperoxide, 
prostaglandin H2 (PGH2), by an enzyme later known as prostacyclin synthase 
{PTGIS, gene; PGIS, protein) (Moncada et al., 1976). Human PTGIS locates on 
chromosome 20ql3.1 l-ql3.13. It consists of 10 exons spanning approximately 60kb 
(Yokoyama et al” 1996; Nakayama et al., 1996) (figure 1.2.1). The 3'-untranslated 
region contains multiple polyadenylation signals. Two transcripts of human PTGIS, 
a major 6 kb and a minor 3.3 kb m R N A , have been shown in human cells by 
Northern blot analysis. Human PTGIS transcripts are longer than those of mouse, rat 
or bovine which has a transcript size of-2.7 kb. The biological meaning of longer 
polyadenylation signals in human PTGIS is unclear (Wu et al, 2005). Translation 
from open reading frame (ORF) of 1500 bp of the transcripts produces a polypeptide 
of 500 amino acids with sequence homology to cholesterol 7-alpha-monooxygenase, 
a member of the CYP7 family of cytochrome P450s (Miyata et al., 1994). 
Molecular weight of PGIS is ~57kDa. 
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Figure 1.2.1 Genomic structure of the human PTGIS. (Solid and striped filling 
represent coding exon and untranslated region respectively) 
1.2.2 Transcriptional control of PTGIS 
The 5-flanking region of PTGIS is TATA less and GC rich, consistent with the 
structural feature of housekeeping genes. Several potential transcription start sites 
are reported to be situated 46-54bp upstream of the ATG translation initiation codon 
(Yokoyama et al., 1996). The region of nucleotides -145 to -10 was shown to have 
basal promoter activity while -1070 to -10 elicited maximal promoter activity 
(Yokoyama et al., 1996). Results from promoter analysis and gel shift assays have 
identified two Spl binding sites as being necessary for constitutive expression of 
PGIS in mouse smooth muscle cells (Ohkawara et al., 2000). There are several 9-nt 
repeats (CCGCCAGCC) in the proximal region of the 5'-untranslated region which 
create several Spl binding sites. These repeats can be considered as Variable 
Number of Tandem Repeats (VNTR) because the number of repeats is polymorphic. 
Report from a study of Japanese population has identified individuals with 3-7 
repeats among which 6 repeats is the most frequent genotype. Variation in the 
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number of repeats alters the number of Spl binding sites. Functional assessment has 
shown a positive correlation between the number of repeats and thus Spl binding 
sites with promoter activity stimulated by interleukin 6 (IL-6). The alleles of 3 and 4 
repeats (SS genotype) had lower promoter activity in cultured human umbilical vein 
endothelial cells. Interestingly, other vasodilator genes expressed in vascular cells, 
such as endothelial nitric oxide synthase, natriuretic peptide receptor A and 
prostaglandin H synthase-1, also require intact Spl sites in their proximal promoter 
for optimal activity (Karantzoulis-Fegaras et al., 1999; Liang et al,, 1999; Xu et al., 
1997). And the vasoconstrictor gene, thromboxane synthase is negatively regulated 
by Spl (Zhang et al., 1997). Thus, the balance of bioactivity between vasodilator 
and vasoconstrictor may mediate in part through the expression of Spl. 
Besides the length of the VNTR, there are also SNPs present and were shown to 
cause different transcriptional activity. In the presence of rs5582-T, the minor allele 
G of rs5580 produced a lower transcriptional activity measured by the luciferase 
reporter assay in human lung cancer cell lines (Stearman et al” 2007). Furthermore, 
there are CpG islands present in exon 1 and first intron of PTGIS. Heavy 
methylation of the CpG islands leads to epigenetic silencing of the PTGIS promoter 
(Stearman et al., 2007). 
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1.2.3 Protein structure of PGIS 
Crystal structure of PGIS was resolved by x-ray crystallography (Chiang et al., 2006) 
and is shown in Figure 1.2.2. While notable sequence divergence has been 
recognized between PGIS and other P450 members, PGIS exhibits the typical 
triangular prism-shaped P450 fold with only moderate structural differences. A 
combination of bent I helix and tilted B’ helix creates a channel extending from the 
heme distal pocket which allows binding of various ligands, but residue W282, may 
serve as a threshold to exclude most ligands from binding. The side-chain of N287 
appears to be positioned to facilitate the endoperoxide bond cleavage. The heme 
group embedded between the I and L helices is involved in substrate binding, 
electron transfer and catalysis. 
Figure 1.2.2 Structure of human 
^ r ^ prostacyclin synthase. Ribbon representation 
a ] ^ y of PGIS viewed from substrate entrance 
channel (shaded circle). The structure is 
, r a i n b o w - c o l o u r e d with the N terminus in blue 
肪 d 仇e c terminus in red. The heme is shown 
J / ^ ^ ^ ^ B O as a stick model in the centre of the molecule. 
^ ^ Q r ^ ^ ^ S S b ^ J ^ y Major helices and p sheets are labeled 
(adopted from Chiang et al. 2006) 
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The large cytoplasmic domain of PGIS is anchored to the endoplasmic reticulum 
(ER) membrane by a single N-terminal membrane-anchor segment (Deng et al, 
2002). 
1.2.4 Sub-cellular localization and tissue distribution 
As mentioned above, the N-terminal membrane-anchor segment makes PGIS 
localized on the cytosolic side of the ER. In the resting bovine aortic endothelial 
cells, PGIS is colocalized with prostaglandin H2 synthase (PGHS) to nuclear 
envelope and ER (Liou et al, 2000). These findings underscore the importance of 
colocalization of PGHS and PGIS to ER and nuclear envelope in prostacyclin 
synthesis as PGHS converts PGG2 to PGH2 which is a substrate for PGIS. In the 
membrane-bound systems, the lipid substrates, arachidonic acid and PGH2 have 
higher efficiency to access the active sites and less chance to be degraded. This is 
supported by the observation that PGHS side-products are much less plentiful in 
biosysnthesis of thromboxane A2 and PGI2 with intact membrane-bound systems as 
compared with solubilized enzymes (Deng et al, 2002). 
PGIS is constitutively expressed in vascular cells such as endothelial cells and 
smooth muscle cells. Recent studies have shown that PGIS is also expressed in 
non-vascular cells/tissues such as heart, lung, ovary, prostate, neurons, embryonic 
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cells and cancer cells (Yokoyama et al, 1996; W u et al., 2005). Gene expression 
data from UCSC (Figure 1.2.3) further indicates that PGIS has high expression in 
cardiac myocytes and adipocyte. The wide-expression of PGIS supports its 
housekeeping gene features like TATA-less from the promoter analysis and extended 
the function of PGIS from vasodilation to neuroprotection, reproduction and cancer 
growth. The expression of PGIS in muscle and adipocyte suggests that PTGIS may 
be involved in energy metabolism. 
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Figure 1.2.3 Relative expression of PTGIS mRNA in various cells and tissues. 
Red indicates high expression and green indicates low expression. Data were cited 
from the UCSC genome browser (http://genome.iicsc.edu/ctd-bin/htzGatewavV 
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1.2.5 Function of PGIS 
Prostacyclin (PGI2) is a metabolite of arachidonic acid, the precursor of 
prostaglandins (PG) in man (Moncada, 1982). Together with other PGs and 
thromboxane A2，PGI2 is produced by two rate-limiting cyclooxygenases (cyclic 
endoperoxides), COX-1 and COX-2 which form the prostaglandin endoperoxide 
PGG2. This is converted to PGH2 by PGHS. PGIS acts as an isomerase to 
transform PGH2 to PGI2 (figure 1.2.4). PGI2 is chemically unstable with a 
half-life of 2-3 min in blood at 37 °C and then breaking down to stable 
metabolite 6-keto-PGFia (Moncada, 1982). The major biological functions of 
PGI2 are as follows: 
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Figure 1.2.4 Metabolic pathways of arachidonic acid into prostaglandins 
(Modified from figure 1 from Moncada, 1982) 
25 
1.2.5.1 Function of PGI2 in blood vessels 
PGI2 is essential to the integrity of the endothelium and contributes to the 
regulation of vasomotion. In blood vessels, particularly larger arteries, the 
predominant prostaglandin is PGI2 (Wu et al., 2005; Zou, 2007). Culturing 
endothelial cells from vascular walls are the most active producers of PGI2 
(Spisni et al., 1995). PGI2 relaxes isolated vascular strips and is a strong 
hypotensive agent through vasodilation of all vascular beds studied, including the 
pulmonary and cerebral circulation (Moncada, 1982). It is also a potent 
endogenous inhibitor for platelet and leukocyte activation. PGI2 can further 
disperse existing aggregates in vitro and in the circulation of human. 
The action of PGI2 in vascular tissues is through binding to a PGI2 receptor (a 
G-protein coupled cell surface receptor termed IP). Activation of IP by an agonist 
leads to increased production of intracellular cyclic 3'5，-adenosine 
monophosphate (cAMP) via stimulation of adenylyl cyclase. This in turn 
activates protein kinase A cascade or calcium mobilization via phospholipase C 
activation (Lim et al.’ 2002). 
1.2.5.2 Role of PGI2 in embryo development 
Oviduct is pivotal for embryo development and transport to uterus. It is 
composed of a layer of epithelial cells lining the lumen, sub-epithelial smooth 
muscle cells and supportive tissues, which resembles that of blood vessels. 
Human and murine oviducts are capable of producing abundant PGI2 (Huang et 
al, 2002). Its level in oviduct reached maximal at day 2-3 after fertilization in 
murine and declined to a level lower than the level of non-pregnant duct at day 4 
and the rise in PGI2 production correlates with an increased expression of COX-2 
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(Huang et al., 2004). PGI2 relaxes oviductal smooth muscle cells and its 
enhanced production may be crucial for maintaining ductal dilation to allow for 
the transport of embryo to the uterus. 
Both COX-2 and PGIS are probably up-regulated at different stages of 
embryonic growth and are expressed in maternal tissues including oviducts and 
uterus as well as embryonic stem cells and trophoblasts. The coordinated 
expression of the two enzymes results in an augmented production of PGI2 which 
is important for embryo development in the oviduct, transport of the developed 
embryo to the uterus and implantation of the embryo. This coordinated program 
is regulated by temporal and spatial transcriptional activation of COX-2 and 
PTGIS and PGI2 exerts its action on embryo implantation by activating a nuclear 
hormone receptor, peroxisome proliferator-activated receptor 5 (PPAR5) (Lim et 
al., 1999). 
1.2.5.3 Role of PGI2 in apoptosis 
Another piece of evidence showing the biochemical relationship between PGI2 
and PPAR5 arises from the pro-apoptotic activity of PGI2. Endogenous 
production of PGI2 activates endogenously expressed PPAR5 in human 
embryonic kidney 293 cells, leading to apoptosis (Hatae et al., 2001). 
1.2.5.4 Targeted knock-out mice phenotype 
Data from Knockout Mouse Project (KOMP) of the Jackson Laboratory 
(available at httD://www.knockoiitniouse.org/) show that targeted knockout of 
murine PGIS causes defects in cardiovascular and renal systems. Part of exon 7 
and all of exons 8 and 9 were replaced by a neomycin resistance gene which 
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leads to knockout of the PTGIS transcript and protein. The PGIS-/- mouse had 
increased blood pressure and abnormal aorta morphology. Vascular congestion, 
fibrosis and necrosis were also observed in the kidney of the knockout mouse. 
Interestingly, renal abnormalities were not found in PGI2 receptor deficient mice 
(Yokoyama et al.，2002). Therefore, it is possible that another signaling pathway 
through PPARS is involved in the development of renal abnormalities. 
1.2.6 Relationship between PTGIS and diseases 
1.2.6.1 Genetic association 
PTGIS genetic polymorphisms have been associated with various diseases 
including cerebral infarction, myocardial infarction and hypertension (Table 1.2.1) 
(Iwai et al., 1999; Nakayama et al., 2000; Nakayama et al., 2002; Nakayama et 
al.’ 2002). 
Table 1.2.1 Genetic association with PTGIS polymorphisms 
Author Year Associated Risk allele and possible 
diseases/traits mechanism 
Iwai et al. 1999 Higher systolic SS genotype (3 and 4 
pressure, pulse repeats) of the V N T R in 
pressure and risk of promoter region, 
hypertension SS genotype had a lower 
transcriptional activity under 
IL-6 stimulation 
Nakayama et al 2000 Cerebral infraction Small number repeat alleles 
of V N T R 
Nakayama et al 2002 Essential hypertension 丁 to C transition at the +2 
position of the splicing donor 
of intron 9 
Skipping of exon 9 producing 
a truncated protein 
Decreased urinary secretion 
of prostacyclin metabolites in 
subjects with mutation 
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Author Year Associated Risk allele and possible 
diseases/traits mechanism 
Nakayama et al 2002 Myocardial infarction CC genotype of a 
synonymous SNP (rs5629) in 
exon 8 
1.2.6.2 Inactivation and tyrosine nitration of PGIS by peroxynitrite 
Peroxynitrite (ONOO ) is a potent oxidant formed by a direct bimolecular 
reaction of nitric oxide with superoxide ion (Beckman et al, 1990). Production of 
superoxide by both endothelial cells and smooth muscle cells can be up-regulated 
under pathological conditions such as hypertension, atherosclerosis or by high 
glucose environment (Harrison, 1997; Zou et al., 2002). Exposure of human 
aortic endothelial cells to high glucose (30 mmol/1) increases formation of 
peroxynitrite, which causes tyrosine nitration and inhibition of PGIS (Zou et al, 
2002). Zou et al. further investigated if PGIS nitration occurs in diabetes (Zou, 
2007). They used a diabetic rat with elevated plasma glucose to probe for PGIS 
nitration. PGIS nitration was found in both endothelium and vascular smooth 
muscle layers. This was further confirmed from the increased 3-nitrotyrosine 
staining in PGIS immunoprecipitated from the aorta of diabetic BB rats, but not 
from control rats. In addition, PGIS activity, as judged by 6-keto-PGFia 
formation from exogenous PGH2 substrate, was 75% lower in diabetic rats than 
in control rats. Similar observations were also observed in LDL receptor-deficient 
and diabetic mice. These data implicated the role of PGIS in endothelial 
dysfunction which is often associated with diabetes. 
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1.3 Biology of peroxisome proliferator-activated receptor delta (PPARD) 
1.3.1 Molecular information of PPARD 
Peroxisome proliferator-activated receptor delta (Gene: PPARD; Protein: PPARS) 
belongs to a superfamily of nuclear hormone receptors relating to retinoid, 
steroid and thyroid hormone receptors. Three PPAR isotypes exist in mammals: a 
(NRICI), y (NR1C3) and 5 (NR1C2). They are products of distinct genes: the 
human PPARa gene is located on chromosome 22ql2-ql3.1, the PPARy gene is 
mapped on chromosome 3p25, whereas PPARD is on chromosome 6p21.2-p21.1 
which is a type 2 diabetes susceptibility locus in Han Chinese (Luo et al., 2001). 
PPARa was the first PPAR to be identified and was demonstrated to be the target 
of fibrate drugs and carcinogens that cause peroxisome proliferation in rodent 
livers, where PPARa is abundantly expressed (Issemann et al., 1990). However, 
neither PPARy nor PPARS do respond to these proliferators (Schmidt et al, 
1992). PPARy is expressed predominantly in adipose tissue and to a lesser extent 
in macrophages, muscle and liver. It has received considerable attention since the 
mid-1990s when it was found to be the molecular target of insulin-sensitizing and 
anti-diabetic drugs known as thiazolidinediones (Lehmann et al, 1995). PPARD 
was cloned in 1992 (Schmidt et al., 1992). The human gene has 9 exons spanning 
~85.6kb in human with exons ranging in size from 84 bp to 2.3 kb and introns 
ranging from 180 bp to 50 kb (Figure 1.3.1) (Skogsberg et al., 2000). m R N A size 
of the major PPARD transcript is 3803 bp. Exons 1-3, 5' end of exon 4 and 3，end 
of exon 9 are unstranslated. Translation of the 1323 bp open reading frame (ORF) 
produces a protein of 441 amino acids. Molecular weight of PPARS is 〜49.9 kDa. 
Besides the major transcript of 3.8 kb, PPARD has at least 11 alternatively spliced 
variants. However, they do not contain new in-frame coding regions. Thus, all the 
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transcripts share the same ORF from exons 4 to 9 (Lundell et al., 2007). 
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Figure 1.3.1 Genomic structure of the human PPARD, (Solid and striped 
filling represent coding exon and untranslated region respectively) 
1.3.2 Transcriptional control of PPARD 
PPARD is transcribed from a unique start site located 380 bp upstream of the 
ATG initiation codon (Skogsberg et al., 2000). PPARD lacks a TATA box and its 
near-ubiquitous tissue expression indicates features of housekeeping genes. 
Numerous studies have aimed at unraveling the physiological role of PPAR5 as a 
transcriptional regulator, but the regulation of PPARD expression has been less 
studied. Studies on murine PPARD promoter revealed several transcription 
factors regulating PPARD transcription, including CCAAT/Enhancer-binding 
proteins (C/EBP)，AP-1 and Yin Yang 1 (YYl). C/EBPa and C/EBPp inhibit the 
expression of PPARD in mouse keratinocyte (Di-Poi et al., 2005) whereas AP-1 
acts as an activator in PPARD promoter (Tan et al., 2004). Recently, YYl was 
shown to repress the promoter activity in Hela and NIH 3T3 cells (He et al., 
2008). 
In addition to the promoter region, the 5’ untranslated region of PPARD also can 
regulate its expression. Skogsberg et al. showed that a SNP (rs2016520) at the 
untranslated region of exon 4 influences the promoter activity. This A/G 
polymorphism affects binding of Sp-1 at the 5' untranslated region of exon 4. The 
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rare G-allele has a higher affinity for Sp-1 and enhances the promoter activity 
(Skogsberg et al.’ 2003). Further studies on the human PPARD promoter and 5' 
untranslated region are needed to understand the transcriptional regulation. 
Figure 1.3.2 summarizes the transcription factors regulating PPARD expression. 
Oct-1, 
YYl AP I C/EBPAP-1 I—> Sp-1 
- I ~ % - m 厂 • 
-927 -494 -414 +1 Exon 4 
to (5，UTR) 
-485 
Figure 1.3.2 Schematic diagram showing transcription factor binding sites 
on PPARD promoter. +1 indicates the position of transcription start site. The 
Oct-1 and AP-1 binding sites in grey colour is the putative site by computer 
prediction (Di-Poi et al., 2005). Other binding sites were proven by experiments. 
(5' UTR, 5' untranslated region) 
PPARD mRNA expression is also influenced by nutrition. It can be 
down-regulated in the liver and kidney by up to 80% after overnight fasting and 
restored to control levels upon refeeding (Escher et al., 2001). This suggests the 
function of PPAR5 as a nutritional sensor. 
1.3.3 Translational control and protein structure 
The production of PPAR5 protein in a cell depends on both the transcription and 
translation efficiency. The alternatively spliced PPARD transcripts can regulate 
the translation efficiency. Longer 5' untranslated region transcripts are less 
efficiently translated into protein in an in vitro transcription/translation coupled 
system (Lundell et al., 2007). This shows that the alternatively spliced transcripts 
have the intrinsic role in regulating its own expression and possible role of this 
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nuclear receptor in physiology and disease. 
The three isotypes of the PPAR family possess a structurally variable 
amino-terminal and hinge regions, but the amino acid sequences in the DNA 
binding domain (DBD) and ligand binding domain (LBD) are conserved up to 
85% and up to 70%, respectively (Rosen et al., 2001) (Figure 1.3.3). 
1 72 137 21S 441 
hPPAR5 
(PPAR^ , Nuc.1, FAAR) w H M H H n H H H M H H H H M H M P 
hPPARoc ^VElritaSiLlll^lHBHtf 
1 110 175 251 477 
1 30 140 MS 281 S07 
Figure 1.3.3 Amino acid sequence comparison of PPAR isoforms. Human 
PPAR5, PPARa and PPARy are represented in linear fashion to display a 
conserved domain structure with a DBD and LBD. Amino acid numbers are 
above each receptor and percent identity is displayed within each domain. 
P P A R y 2 has 30 extra amino acids when compared to PPARyi. (Adopted from 
Rosen et al. 2001) 
Crystal structure of LBD of PPAR6 was solved in 1999 (Xu et al., 1999). The apo 
PPAR5 LBD folds into a single domain that contains a bundle of 13 a helices and 
4 small stranded p strands. Helices 4, 5, 8 and 9 are sandwiched between helices 
1，3, 7 and 10 at the top half of the LBD (Figure 1.3.4a and b). Helices 3，7 and 
10 form the scaffold for the cavity of the ligand binding site, which is present in 
the bottom half of the protein (figure 1.3.4c). The ligand binding pocket is a very 
large cavity of � 1 . 3 nm ,^ which is comparable to that of PPARy but much larger 
than the pockets of other nuclear receptors. The increased dimension is believed 
to accommodate the binding of various fatty acids or other amphipathic acids to 
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PPAR5 via hydrogen bonds and hydrophobic interactions (Xu et ai, 1999). 
•翻 
Figure 1.3.4 The apo PPARS crystal structure, (a and b) Two views differing 
by 90° of the structure of the apo PPARS LBD (amino acids 210476) are 
presented in a solid render. The three layers of alpha-helical sandwich are shown 
in red，purple, and blue, respectively. Beta strands are shown in yellow and the 
loops in white, (c) Worm drawing of the PPARS backbone. The total volume of 
the pocket is approximately 1.3 nm .^ The backbone is colored according the 
temperature factor profiles of the polypeptide backbone atoms, (d) The channel 
providing access to the ligand binding pocket is shown by a surface presentation 
of the protein. The surface is colored according to electrostatic potential (blue, 
positive; red，negative; white, neutral). (Adopted from Xu et al 1999) 
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1.3.4 Sub-cellular localization and tissue expression 
According to expression profiling of PPAR5 in adult mouse tissues generated 
from tissue microarray based immunohistochemistry (Higashiyama et al, 2007), 
PPAR5 was generally localized in the nucleus. Cytoplasmic localization was 
observed on several cell types including neurons and cells of the islet of 
Langerhans. In the tissues/cells level, PPAR5 was observed in multiple systems 
including cardiovascular, urinary, respiratory, digestive, endocrine, nervous, 
hematopoietic, immune, musculoskeletal, sensory and reproductive organ 
systems. This shows the ubiquitous feature of PPAR5 expression. Moreover, the 
expression level of PPAR5 is the most abundant among the three PPARs in most 
tissues (Table 1.3.1) (Takahashi et al.’ 2006). PPARS is expressed in skeletal 
muscle at 10- and 50-fold higher levels compared with PPARa and PPARy 
respectively (Braissant et al” 1996). 
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PPAR 
“ ^ ~ 
_ — 
Telencephalon 
Olfactory bulbs " + + • t 
Cortex 上 +1- -
Hippocampus: 
CAl + + + + -
CA3 r + + + — 
Dentate gyrus 十 H ± 
Dicnccphalon 
Thalamic nuclei ± + + -
Hypothalamic nuclei ± • -
Retina 
Inner nuclear layer + + + 卞•^“十 + • 
Outer nuclear layer + + + + + + + + 
Ganglion cells - - + 
.Midbrain 
(^olliculi + -
Kcd nucleus - + 貪 _ 一 
Brainslem 
Vcsticuiar nuclei - • + + i 
R«ticular formation _ -
Cerebellum 
Molecular layer - + 
Furkiryc cclU 一 • + + -
Gninule cells + + + + , 
Dwp nuclei - + + -
Choroid plexus + + + -
Epidermis 
KeratinocyUs (from Stratum basale to - -
Stratum comeum) 
Sebaceous glands and hair follicles + + + 4 -
Kidney 
Glomeruli + ++ t 
Proximal tubules • + + + + + * 
Hcnic'fl loops 一 • * »• -
Distal lobulett - ••中 一 
Collecting ducts - -
Liver 
Hopatocytcji •*•/•• ++ -
Pancreas 
Acini (exocrine) + + + + 
IsleU (endocrinc) ^ ++ + 
Heart 
Cardiomyocytes 一 办 一/••办 -
White adipose tisflue + + + + + 
Immune system 
Spleen 
While pulp 十 * + + + • • » f 
IRed pulp + + + + + 
Pcycr'ft patchctt + + + + + +令 
Di(festive tract 
Smooth muscular layers - 一 一 
Rsophagut 
Keratinoc>nes ++ + + • 
Submucosu + ++ + + 
Stomach 
Chief cells " “ + 
rorietal cells ++ ‘ 
Mucuk CCIIK + + + H + 
Duodenum 
Crypt cntcrocytcs h • f + • + + + 
Villi ent^rocyles + + + + + + • »^ 
Gobclet cclU + + + + 令+ + + + 
Brunner's gland - - 一 
Jejunum crypts and villi • • • 个+ • + + 
Ileum cryptK and villi + + + + + 
Cecum * * •十 + + 
Colon + • + 
Genital »y»tem 
Tc«tis 
Spormatogonia to spormatozoan - - -
Sertoli ccWs + + • » • t rt 
Le>dig c«lls + + — 
Ovary 
Follicular cells “ ++ ^ 
Oocyte - -
Seminal gland epithelium » * + + + + 
Uterus 
Cervix t 
Uterine glands + f i t 
Fallopian duct epithelium i t + • + 
Table 1.3.1 PPARs mRNA expression in adult rat. (PPARp is the same as 
PPAR5.) a -，absent; 士，barely detectable; + weak expression; ++，moderate 
expression; +++，strong expression; ++++ very strong expression. — or + signs 
reflect differences in signal intensities observed by optical microscopy. The 
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number of + signs do not represent a strictly linear measure of m R N A levels. ^  In 
liver (PPARa) and heart (PPARa and (3), expression varies between individuals, 
(modified from Braissant et al 1996) 
1.3.5 Function ofPPARS 
PPAR5 is a powerful transcription factor in glucose and lipid metabolism. It 
responds to various lipids and their metabolites and turns on metabolic gene 
expression to regulate glucose and lipid homeostasis. 
1.3.5.1 Mechanisms of action 
In the nucleus, PPARs heterodimerize with the 9-c/5-retinoic acid receptor (RXR) 
and bind to specific D N A sequence called PPAR responsive element (PPRE). 
PPRE has the sequence A G G T C A N A G G T C A (also known as direct repeats of 
hexameric D N A sequences with a single nucleotide spacer [DRl]) (Figure 1.3.5) 
(Kliewer et al., 1992). A short sequence located immediately upstream of the first 
half-site confers polarity on the PPRE, with the PPAR moiety binding 5’ to the 
R X R half of the heterodimer (Rosen et al., 2001). In the absence of ligand, 
PPAR-RXR heterodimers recruit corepressors and associated hi stone 
deacetylases and chromatin-modifying enzymes, silencing transcription by a 
process called active repression. Ligand binding induces a conformational change 
in PPAR-RXR complexes, releasing repressors in exchange for coactivators. 
Ligand-activated complexes recruit the basal transcriptional machinery, resulting 
in enhanced gene expression (Barish et al., 2006). 
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Figure 1.3.5 Molecular mechanism of PPAR8 action in the nucleus. 
1.3.5.2 Ligands for PPAR6 
Unlike classical endocrine receptors that bind to high-affinity glandular 
hormones, PPARs bind to lower-affinity ligands generated from dietary fat or 
intracellular metabolism. Several 14- to 18-carbon saturated fatty acids as well as 
16- to 20-carbon polyunsaturated fatty acids are suggested to bind PPAR5 based 
on ligand screens and competition binding assays, with affinities in the 
micromolar range (Xu et al.’ 1999; Forman et al., 1997). Other naturally 
occurring ligands include PGI2 (and its synthetic counterpart carbaprostacyclin) 
and very low density lipoprotein (VLDL). As VLDL particle-derived fatty acids 
enhance the expression of PPAR5 target genes in a receptor-dependent manner, 
suggesting a variety of VLDL-delivered fatty acids could serve as endogenous 
receptor agonists (Chawla et al.’ 2003). Alternatively, combinatorial chemistry 
and structure-based drug design have facilitated the development of synthetic 
agonists with nanomolar affinities for PPARS (Barish et al, 2006). One of the 
most widely studied selective PPARS agonists is GW501516. 
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1.3.5.3 PPAR8 in lipoprotein metabolism 
A hallmark of the metabolic syndrome is dyslipidemia, marked by elevated 
triglycerides and low levels of H D L cholesterol. H D L is a driving force in the 
process of reverse cholesterol transport, reclaiming excess peripheral tissue 
cholesterol to the liver for excretion. High-affinity PPAR5 ligands have revealed 
an important role for PPARS in lipoprotein metabolism. 
Treatment of insulin-resistant obese rhesus monkeys with PPAR5-specific 
agonist GW501516 resulted in a dramatic 79% increase in HDL-C, a 56% 
decrease in triglycerides and a 29% decrease in LDL cholesterol. The increase in 
HDL-C levels was correlated with an increase in number, not size, of H D L 
particles and was accompanied by increased serum levels of the HDL-associated 
apolipoproteins, apoAI, apoA-II and apoC-III (Oliver et al, 2001). Obese and 
non-obese mice similarly develop an increase of up to 50% in HDL-C levels 
when treated with PPAR5 agonists (Leibowitz et al, 2000; van der Veen et al, 
2005). This HDL-C elevating effect may be due to enhanced expression of 
reverse cholesterol transporter, ATP-binding cassette Al (ABCAl) in 
macrophages or reduced expression of a key mediator in intestinal cholesterol 
absorption, Niemann-Pick CI-like 1 gene (NPCILI) (Oliver et al, 2001; van der 
Veen et al., 2005). Based on these findings, PPARS agonists are now in clinical 
trial for the treatment of human dyslipidemia (Barish et al” 2006). 
1.3.5.4 PPARS action in adipose tissue 
Adiposity is believed to be primacy in the metabolic syndrome and correlates 
with insulin resistance (Carr et al, 2004). Administration of GW501516 to 
genetically obese {db/db) mice reduced intracellular triglyceride accumulation in 
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the brown fat and liver (Wang et al., 2003). Moreover, GW501516 enhanced 
P-oxidation in 3T3-L1 preadipocytes by 50% and retarded weight gain in high fat 
fed mice (Wang et al., 2003; Tanaka et al., 2003). These results suggest that 
PPAR5 agonists may be therapeutic as anti-obesity agents. Short-term (4-month) 
treatment of obese rhesus monkeys with variable doses of GW501516 did not 
affect body weight, however, the effect of long-term treatment in monkeys and 
humans remains to be determined (Oliver et al., 2001). 
1.3.5.5 PPARS action in skeletal and cardiac muscle 
Skeletal muscle is a key metabolic tissue, accounting for - 8 0 % of 
insulin-stimulated glucose uptake. It is composed of three types of myofibers, 
oxidative slow-twitch (type I), mixed oxidative/glycolytic fast-twitch (type IIA) 
and glycolytic fast-twitch (type I IB) forms (Pette et al, 2000). Oxidative 
myofibers preferentially express enzymes that oxidize fatty acids and contain 
slow isoforms of contractile proteins, whereas glycolytic myofibers 
predominantly metabolize glucose and are composed of fast contractile protein 
isoforms (Pette et al.’ 2000). Targeted expression of constitutively active viral 
protein 16-PPAR5 (VP16-PPAR5) in rodent skeletal muscle increases the 
proportion of slow-twitch muscle fibers (Wang et al., 2004). The observed 
PPAR5-mediated muscle fiber reprogramming involves the increased expression 
of genes related to fatty acid oxidation, mitochondrial respiration, oxidative 
metabolism and slow-twitch contractile apparatus. Treatment of rodents with 
GW501516 leads to similar increase in gene expression (Wang et al., 2004). 
Moreover, activation of PPARS in cultured skeletal muscle L6 myotubes 
increases the expression of genes related to oxidative metabolism (Tanaka et al, 
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2003). In vitro studies also show that PPAR5 agonists treatment of cultured 
human skeletal muscle increases insulin-dependent glucose uptake (Kramer et al, 
2005). PPAR5 regulation in metabolic status and fiber type has several 
physiological implications. First, the presence of an increased proportion of 
oxidative slow-twitch fibers can improve fatty acid homeostasis and become 
resistant to high-fat diet induced obesity in VP16-PPAR5 transgenic mice (Wang 
et al” 2004). Second, this effect is analogous of endurance training and can 
increase oxidative capacity and utilization of lipid in skeletal muscle (Barish et 
al.，2006). 
In rat cardiac muscle, activation of PPAR5 also increases fatty acid oxidation 
through the induction of oxidative genes (Cheng et al” 2004). This has an 
important effect as fatty acid oxidation is the primary source of energy in the 
postnatal heart (Barish et al, 2006). A list of genes regulated by PPAR5 in fat and 
muscle tissues is provided in Table 1.3.2. 
Table 1.3.2 PPAR5 gene targets in fat and muscle tissues 
Process Brown White Skeletal Muscle Cardiac 
fat Fat muscle 
Fatty acid LCAS, Heart fatty I-CPTU 
transport and VLCAS, acid-binding protein, m-CPTl, 
oxidation AC0X1, Fatty acid transport thiolase, 
m-CPTl, pwtein/CD36, UCP3, LCAD, 
LCAD, m-CPTl, PDK4, MCAD, 
VLCAD, HMGCS2, thiolase, PDK4, 
HSL LCAD VLCAD, 
ACOXl 
Mitochondrial UCPl, UCPl Cytochrome c, 
respiration and UCP3 Cytochrome oxidase II 
thermogenesis and IV, UCP2, UCP3 
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Process Brown White Skeletal Muscle Cardiac 
fat Fat muscle 
Oxidative Succinate 
metabolism dehydrogenase, citrate 
synthase 
Slow-twitch Myoglobin, troponin I 
fibers formation slow 
ACOXl, acyl-CoA oxidase., HMGCS2, 3-hydroxy-3-methylglutaryl-CoA synthase 2; 
HSL, hormone-sensitive lipase; LCAD, long-chain acyl-CoA dehydrogenase; LCAS, 
long-chain acyl-CoA synthetase', l-CPTl, liver carnitine palmitoyltransferase 1; 
MCAD, medium-chain fatty acyl-CoA decarboxylase-, m-CPTl, muscle carnitine 
palmitoyltransferase 1; PDK4, pyruvate dehydrogenase kinase 4\ UCP, Uncoupling 
protein., VLCAD, very-long-chain acyl-CoA dehydrogenase', VLCAS, very-long-chain 
acyl-CoA synthetase. (Modified from Barish et al. 2006) 
1.3.5.6 PPARS action in liver 
PPAR5 activation with GW-501516 in dbldb mice activates the pentose 
phosphate shunt and promotes fatty acid synthesis in the liver (Lee et al, 2006). 
The activity of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme in 
the pentose phosphate pathway, was increased by 2-fold in livers of the 
GW-treated dbldb mice compared with the control group. The conversion rate of 
''^ C-labeled glucose into TG and fatty acids increased by ~2-fold in GW-treated 
primary hepatocytes. The increase in fatty acid synthesis is due to higher 
expression of fatty acid synthase {FAS) in the liver. The upregulation of these two 
processes can increase glucose consumption and reduce hepatic glucose output. 
1.3.5.7 PPARS and endocannabinoid system 
The expression of CBl receptor in adipocyte is regulated by PPARS (Yan et al, 
2007). In 3T3-Ll-preadipocyte, selective silencing of PPARS by R N A 
interference significantly increased CBl expression whereas 
adenovirus-mediated overexpression of PPAR5 significantly reduced CBl 
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expression. Furthermore, high fat diet increased the expression of CBl receptor 
together with the decrease in PPARS in rats. 
1.3.5.8 PPAR8 action in inflammation 
PPAR5-null macrophage expressed decreased levels of inflammatory mediators 
including monocyte chemoattractant protein (MCP-1), IL-1(3, while 
overexpressing PPARS produced increased levels of inflammatory markers (Lee 
et al., 2003). PPAR5 ligands inhibited inflammatory gene expression in 
macrophages. The pro- and anti-inflammatory effect of PPAR5 can be explained 
by the interaction of PPARS and B cell lymphoma-6 (BCL-6). BCL-6 is an 
inflammatory suppressor protein which is released from PPARS in a 
ligand-dependent manner and suppresses inflammatory gene expression. While in 
overexpression of PPAR5, BCL-6 is captured and causes increased levels of 
inflammatory markers (Lee et al., 2003). Therefore, administration of PPARS 
agonists should ameliorate inflammation. 
Figure 1.3.6 summarizes the function of PPARS in targeting metabolic syndrome. 
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Figure 1.3.6 PPARS as a therapeutic target in the metabolic syndrome. 
PPAR5 activation improves multiple aspects of the metabolic syndrome through 
tissue- and cell-specific effects. (Adopted from Barish et al. 2006) 
1.3.5.9 Targeted knock-out mice phenotype 
Three independent homozygous PPAR5-/- mice lines have been established by 
deleting different region of the PPARD gene. First, Gonzalez and colleagues 
established PPAR5-/- mice lacking the last 60 amino acids of the ligand-binding 
domain (Peters et al, 2000). The mice have defects in placenta and myelination, 
reduced adipose stores and impaired wound healing. Second, Evan's group 
eliminated DNA binding domain of PPARD by homologous recombination in 
mice (Barak et al., 2002). Over 90% of the PPAR5-/- fetus died in midgestation. 
The surviving knock-out mice are extremely lean. This effect was not reproduced 
in adipose-specific PPAR5-/- mice and they suggested that peripheral PPARS 
functions in systemic lipid metabolism (Barak et al, 2002). The third knock-out 
mice generated by Desvergne's group which lack DNA binding domain also lead 
to embryonic lethality (Nadra et a/.，2006). 
1.3.5.10 Disease association 
PPARD gene polymorphisms and their interactions with other genes have been 
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associated with various diseases including the risk of diabetes and some 
metabolic traits in epidemiological studies (Table 1.3.3) (Skogsberg et al., 2003; 
Vanttinen et al, 2005; Aberle et al., 2006; Andrulionyte et al., 2006; Hu et al., 
2006; Robitaille et al., 2007). 
Table 1.3.3 Genetic associations of PPARD polymorphisms 
Author Year Associated Risk allele and possible 
diseases/traits mechanism 
Skogsberg et al. 2003 LDL-C Rare G allele of rs2016520 
associated with higher 
LDL-C in healthy men; 
Interacted with PPARa 
LI62V to influence LDL-C 
and plasma TG; 
G allele has a higher 
transcriptional activity 
Vanttinen et al. 2005 Skeletal muscle rs6902123, rs2076167 and 
glucose uptake rs 1053049 associated with 
(SMGU) S M G U level 
Aberle et al 2006 B M I rs2016520-A associated with 
higher B M I in a group of 
moderately obese Caucasian 
men and women; 
Interacted with PPARa 
LI62V on B M I 
Hxiet al. 2006 Fasting plasma rs2016520-G associated with 
glucose (FPG) higher FPG in type 2 diabetic 
and normal glucose tolerance 
subjects 
Andrulionyte et al. 2006 Risk of conversion Female carriers of 
from IGT to type 2 rs6902123-C had 2.7-fold 
diabetes increase in the risk of 
conversion from IGT to type 
2 diabetes 
Robitaille et al. 2007 HDL-C level rs2016520 interacts with fat 
intake to influence HDL-C 
level 
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1.4 Functional relationship of PGIS and PPARS: possible role in energy 
metabolism 
PGIS and PPARS have a close biochemical relationship. PGIS converts PGH2 to 
PGI2. The signaling of PGI2 through its cell surface receptor prostacyclin receptor 
(IP) is well documented in vascular biology (Lim et al, 2002). Activation of IP 
increases intracellular c A M P production and leads to vasodilation or 
anti-coagulation. Recently, PGI2 action through nuclear receptors in other 
physiological responses is gradually being better appreciated, especially PPARS. 
Several independent reports showed that PGI2 analog or endogenously produced 
PGI2 activates PPAR5 in vitro. Lim and his colleagues used COX-2-/- mice to 
demonstrate that PGI2 analog cPGI can restore embryo implantation, whereas 
PPARS agonist L-165041 also exerts a similar effect (Lim et al., 1999). This 
implies that cPGI rescues embryo implantation in COX-2-/- mice through 
activation of PPARS. Overexpression of PGIS and increased level of PGI2 
induced apoptosis of human embryonic kidney 293 cells. The apoptotic activity 
of PGI2 is blocked by knockdown of PPARS with antisense oligonucleotide, 
dominant negative expression of a mutant PGIS or mutant PPARS (Hatae et al., 
2001). This shows that endogenously produced PGI2 is an activator of PPARS. A 
similar observation was found in human colon cancer (Gupta et al., 2000). 
Furthermore, PGIS expresses in non-vascular tissues, such as heart, lung, ovary, 
cardio-myocytes and adipocyte. All these evidence suggest the roles of PGI2 
beyond those in vascular tissues. 
PPAR5 is a lipid sensor and transcription factor involved in glucose, lipid and 
energy metabolism. As discussed above, it regulates fatty acid transport and 
oxidation, thermogenesis, hepatic glucose production and HDL-C level. Together 
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with the high expression of PGIS and PPAR5 in adipocyte, it is likely that PGIS 
and PPAR5 work together through PGI2 to regulate energy metabolism. 
1.5 Methods for studying genetics of type 2 diabetes and linkage analysis results 
For the identification of susceptibility genes for type 2 diabetes, two main 
strategies have been adopted: Genome-wide scan and candidate gene approach. 
1.5.1 Genome-wide scan 
Genome-wide scan can be divided into two types, linkage analysis and 
genome-wide association analysis. Linkage analysis can identify chromosomal 
regions susceptible for the disease (Ghosh et al., 1996). For linkage analysis, 
particular regions of the genome of interest or entire genome are scanned with 
highly polymorphic markers, such as microsatellites to find statistical signals 
indicating the probability of co-segregation of the disease with a specific 
chromosomal locus. Once identified, a signal is defined as a linkage between the 
chromosomal locus and the trait investigated. Further fine mapping may be 
required to narrow down the linkage region. The technique is based on the 
rationale that family members sharing a specific phenotype will also share 
chromosomal regions surrounding the gene involved. The main advantage is that 
no prior knowledge or assumptions about the importance of specific genomic 
regions or genes are needed. 
The most promising, replicated findings of linkage regions of type 2 diabetes are 
on chromosomes Iq2l-q24, 2q37, I2q24 and chromosome 20 (Demenais et al., 
2003). The linkage of type 2 diabetes on chromosome 20 was replicated in 
Caucasian and Finnish sibpairs (Bowden et al., 1997; Ghosh et al., 1999; Ji et al, 
1997). Further fine mapping indicated the linkage region on chromosome 
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20ql3.1-ql3.2 (Klupa et al., 2000) which PTGIS also is located on. These 
observations provide rationale for testing PTGIS for association with type 2 
diabetes. 
Recently, with the advances in genotyping technology, it is possible to genotype 
over three hundred thousand SNPs across the genome and this makes the 
genome-wide association studies (GWAS) in case control population feasible. 
With the much higher marker density, the associated region can be narrowed 
down to a single gene or nearby region. G W A S have led to identification of new 
susceptibility gene, including TCF7L2 and SLC30A8 (Scott et al” 2007; Sladek 
et al., 2007). TCF7L2 encodes a 丁-cell-specific transcription factor and the risk 
alleles of TCF7L2 have been associated with lower insulin secretion capacity in 
healthy subjects (Damcott et al., 2006). SLC30A8 encodes the zinc transporter 
protein member 8, which is important for storage and maturation of insulin in the 
granules of the beta cells (Chimienti et al, 2004). 
1.5.2 Candidate gene approach 
The candidate gene approach is based on the current understanding of 
pathophysiology of type 2 diabetes, and is therefore focused on genes involved in 
insulin secretion, insulin action, obesity, lipid and glucose metabolism (McCarthy 
et al., 2002). The target gene is then analyzed for polymorphisms or mutations 
and the frequencies of the markers of interest are tested in association studies. 
Despite the modest contribution of a single genetic variant at the individual level, 
many genes and their variants have been associated with the risk of type 2 
diabetes. The most promising candidate genes include PPARy, insulin receptor 
substrate and the potassium inwardly rectifying channel 11 {KCNJll) (Demenais 
et al., 2003). 
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1.6 Hypothesis and objectives 
Based on the close biochemical relationship between PGIS and PPAR5, the 
linkage of PTGIS-flanking genomic region to type 2 diabetes and the role of 
PPAR5 in lipid and glucose metabolism, the present study hypothesizes that 
genetic polymorphisms in PTGIS and PPARD associate with type 2 diabetes and 
the related metabolic traits. To test this hypothesis, a case-control study 
consisting of 1225 individuals was conducted. Study design and results will be 
presented in Chapter 2. 
If the above hypothesis is substantiated, a second hypothesis that the associated 
SNP(s) is functionally active will be tested using bioinformatics, molecular and 
cellular biology approaches. 
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Figure 1.6.1 Research design. Selected SNPs in PTGIS and PPARD will be 
genotyped in a type 2 diabetes case-control cohort to test for association with type 2 
diabetes and the related metabolic traits. The potential function of any significantly 
associated SNP(s) will be investigated using bioinformatics and molecular studies 
approaches. 
1.7 Long-term significance 
Diabetic epidemic will continue to expand as the prevalence of obesity grows. 
The latest genotyping technologies, development of bioinformatics tools and 
publically available databases enable us to identify more and more disease 
susceptibility genes. The study of genetic variants in PTGIS and PPARD will 
promote the understanding of the roles of these genes and their variants in 
diabetes and in cellular functions. In the long run, the associated and functionally 
active polymorphisms may be useful as genetic markers for the development of 
diagnostic tests or therapeutic tools for high risk individuals. 
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Chapter 2: Association Study of Prostacyclin Synthase and 
Peroxisome Proliferator-Activated Receptor Delta Gene 
Polymorphisms with l y p e 2 Diabetes and Related Metabolic Traits 
2.1 Introduction and research design 
Type 2 diabetes mellitus accounts for most individuals with non-autoimmune form 
of diabetes mellitus. In Hong Kong, approximately one in ten adults have this 
chronic disease. Type 2 diabetes is a heterogeneous and multi-factorial metabolic 
disorder, where the risk of an individual is caused by the complex interplay 
between genetic factors and environmental exposures (Owen et al, 2007). Type 2 
diabetes and its intermediate traits show appreciable heritability and this indicates 
the role of genetic variation in pathogenesis and epidemic of this disease (Stumvoll 
et al, 2005). 
Prostacyclin synthase gene {PTGIS) is located in one of the type 2 diabetes 
susceptibility locus 一 the long arm of chromosome 20. Several linkage analysis 
studies in different population have replicated this susceptibility locus including 
the Han Chinese (Bowden et al., 1997; Ghosh et al, 1999; Klupa et al., 2000; Luo 
et al., 2001). Also, PTGIS gene polymorphism was associated with risk of 
hypertension, which is a risk factor for type 2 diabetes (Yamada et al, 2006). 
PTGIS encodes an enzyme involved in the arachidonic acid metabolism. It is 
mainly expressed in endothelial cells, smooth muscle cells and adipocytes and 
catalyzes the conversion of prostaglandin H2 (PGH2) to prostacyclin (PGI2). The 
traditional role of PGI2 is considered to be controlling platelet reactivity, vascular 
protection and smooth muscle contractility via PGI2 receptor coupled intracellular 
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signaling pathway thereby inhibiting platelet aggregation and dilating blood 
vessels (Wu et al., 2005). Interestingly, recent studies have shown that PGI2 is also 
an endogenous activator of peroxisome proliferator-activated receptor (PPAR)-5 
(Lim et al., 1999), which implies that PTGIS may be involved in energy 
metabolism. 
PPARS is a ubiquitously expressed transcription factor belonging to a 
ligand-activating nuclear receptor family and is located in one of the type 2 
diabetes susceptibility loci in Han Chinese (Luo et al., 2001). It activates target 
gene transcription through the binding to PPAR responsive element as a 
heterodimer with 9-c/5-retinoic acid receptor (Takahashi et al, 2007). PPAR5 is a 
potent regulator of lipid and glucose metabolism (Furnsinn et al., 2007). In skeletal 
muscle, activation of PPAR5 stimulates fatty-acid transport and oxidation as well 
as enhances thermogenesis (Dressel et al., 2003; Tanaka et al., 2003). 
Over-expression of PPAR5 in adipose tissue can improve lipid profile, enhance 
free fatty acid oxidation and prevent obesity and hyperlipidemia in high-fat diet 
fed mice (Wang et al, 2003). Also, PPARS activation suppresses hepatic glucose 
output, contributing to improved glucose homeostasis (Lee etal, 2006). Treatment 
with synthetic PPAR5 agonist lowers fasting insulin in insulin-resistant monkeys 
(Oliver et al., 2001). Previous studies have demonstrated that SNPs in PPAR5 gene 
{PPARD) were associated with cholesterol and fasting plasma glucose levels 
(Skogsberg et al., 2003; Hu et al., 2006). 
Given the biochemical relationship between PTGIS and PPARD gene products as 
well as the role of PPAR5 in energy metabolism, the present study aimed to 
examine the single nucleotide polymorphisms (SNPs) in PTGIS, PPARD and their 
interactive effects on the risk of type 2 diabetes and the related metabolic traits in a 
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case-control cohort consisting of 1225 Hong Kong Chinese. 
2.2 Study population 
2.2.1 Ethics approval 
Informed consent was obtained for each participating subject. This study was 
approved by the Clinical Research Ethics Committee of the Chinese University of 
Hong Kong. 
2.2.2 Subjects 
All subjects were of southern Han Chinese ancestry residing in Hong Kong. The 
population consisted of 630 unrelated early-onset (diagnosed <40 years) type 2 
diabetic patients selected from Hong Kong Diabetes Registry (Yang et al, 2007) 
and 595 non-diabetic control subjects [fasting plasma glucose (FPG) <6.1 mmol/1] 
recruited from the general population participating in a community-based 
cardiovascular risk screening program as well as hospital staff. The use of the 
early-onset patients aims to enrich the genetic background. A balanced 
case-control sample size provides better power to detect significant association. 
2.2.3 Clinical assessments 
All subjects recruited in this project underwent a comprehensive clinical 
assessment. Apart from documentation of demographic data and anthropometric 
assessment, fasting blood samples were taken for measurement of plasma glucose, 
HbAic, lipid profile (triglycerides [TG], total cholesterol [TC], HDL-C and 
calculated LDL-C) and for extraction of genomic D N A . Details of assessment 
method and laboratory assays have been previously described (Tong et al., 2004). 
The components of metabolic syndrome (MES) is defined according to National 
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Cholesterol Education Program (NCEP) with modification of Asian criteria, 
including: 1. Diabetes: FPG >6.1 mmol/1; 2. Hypertension: systolic blood 
pressure (SBP) >130 m m H g or diastolic blood pressure (DBP) >85 m m H g or on 
anti-hypertensive drug treatment; 3. High triglycerides: plasma T G >1.7 mmol/1; 
4. Low HDL-C level: plasma HDL-C <1 mmol/l in male and <1.3 mmol/1 in 
female; 5. Obesity: by Asian criteria, waist circumference >90 cm in male and 
>80 cm in female. An individual is said to have metabolic syndrome if the person 
has 3 out of 5 of the above complications. Table 2.2.1 shows the clinical 
characteristics of the study population. 
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Table 2.2.1 Clinical characteristics of the study population 
Type 2 diabetes Non-diabetic p value^ 
patients controls 
(n = 630) (n = 595) 
Sex (meniwomen, n) 246:384 267:328 -
Age (years) 40.07士8.39 41.37土 10.48 0.016 
Diabetes duration (years) 7.51±7.39 - -
BMI (kg/m^) 25.71 士4.60 22.92士3.30 <0.001 
WHR 0.864士0.068 0.821 士0.073 <0.001 
SBP (mmHg) 125.12 士 18.03 115.23士 16.43 <0.001 
DBP (mmHg) 75.29士 10.37 72.18士 U.28 <0.001 
FPG (mmol/l) 8.95±3.38 4.83±0.41 <0.001 
HbAic (%)" 7.91±1.98 - -
TG (mmol/l) 1.84士2.13 1.10士0.79 <0.001 
TC (mmol/l) 5.31 士 1.16 5.04土0.95 <0.001 
HDL-C (mmol/l) 1.25士0.37 1.56士0.43 <0.001 
LDL-C(minoi/l) 3.28 士0.92 3.00士 0.83 <0.001 
Obesity (Asian criteria for 46.5% 14.5% <0.001 
obesity: waist > 90 in male, 
waist > 80 in female) (%) 
Hypertension or treatment (%) 29.5% 11.8% <0.001 
Low HDL-C (o/o) 45.9% 14.8% <0.001 
High Triglyceride (%) 35.1% 14.2% <0.001 
With MES (%) 51.1% 4.2% <0.001 
Values are expressed as mean士SD or percentage, 
a HbAic level was measured in diabetic patients only. 
b Comparison was performed using Student's t-test or x^ -test where appropriate. 
W H R , waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; FPG, fasting plasma glucose; HbAic, glycosylated hemoglobin; TG, 
triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; 
LDL-C, low-density lipoprotein-cholesterol; MES, metabolic syndrome. 
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2.3 Materials and methods 
2.3.1 DNA samples 
D N A samples were provided by Prof. Juliana Chan and Prof. Maggie Ng of 
Department of Medicine and Therapeutics, Prince of Wales Hospital, The 
Chinese University of Hong Kong (CUHK) (Shatin, Hong Kong). The samples 
were in TE buffer with a concentration of 20 ng/jil, which were shipped to and 
stored at Genome Quebec Innovation Centre at McGill University (Montreal, 
Canada) for genotyping. 
2.3.2 Marker selection 
The markers used in this association study were single nucleotide polymorphisms 
(SNPs). All SNPs were selection from dbSNP of NCBI (National Center for 
Biotechnology Information, Bethesda, M D ) with reference to Han Chinese allele 
frequencies in HapMap (http://www.hapmap.org/) (HapMap, 2003) if available. 
For the SNPs selected in PTGIS, the percentage of conserved identity from 
cross-species alignment of human, mouse (Mus musculus), dog {Canis familiaris) 
and cow {Bos taurus) was also considered. Ten SNPs were selected in PTGIS: 2 
SNPs in the promoter region (rs5580, rs5583), 7 SNPs from intron 6 to exon 8 
and rs5600 in the 3, untranslated region (Figure 2.3.1a). Two SNPs (rs6902123 
and rs2016520) were selected in PPARD based on association studies reported 
(Figure 2.3.1b). rs6902123 was associated with skeletal muscle glucose uptake 
and risk of conversion from IGT to type 2 diabetes (Vanttinen et al., 2005; 
Andrulionyte et al., 2006) whereas rs2016520 was associated with LDL-C and 
FPG levels (Hu et al； 2006; Skogsberg et al., 2003). 
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(a) PTGIS (chromosome 20: 47618114 - 47553818) 
rs7267348 
rs5580, rs5583 rs508757, rs575253 rs5629 rs5600 
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(b) PPARD (chromosome 6: 35418313 - 35503931) 
rs6902123 rs2016S20 
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Figure 2.3.1 Schematic diagram showing SNP positions in (a) PTGIS and (b) 
PPARD and their respective genomic alignment. This precomputed genomic 
sequence alignment was obtained and modified from VISTA homepage, 
http://genonie.lbl.gov/vista/index.shtml/. Purple colour indicates the conserved 
exons, pink colour represents conserved non-coding sequences (over 70% 
identity) and the untranslated region is in light blue. 
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2.3.3 Genotyping 
Genotyping was performed using multiplexing assay for homogenous 
M a s s E X T E N D (hME). h M E involves primer extension of multiplex products 
with detection by matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectroscopy on a MassARRAY platform (Sequenom, San 
Diego, CA) (Figure 2.3.3 on next page). The service was provided by Genome 
Quebec Innovation Centre at McGill University. In h M E assay, one single panel is 
able to genotype as much as 34 SNPs on a 96-well plate (92 test samples and 4 
Sequenom internal references). Thus, genotyping of 1225 samples required 14 
plates. On each plate, there were two blind duplicate samples (4 samples) to 
check for intra-plate concordance. 
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( A ) Amplification (For simplicity, this figure 
depicts a single assay) 
h M E - I O t a g ^ _ ^ . 
V Forward PGR primer 
5: | (7T| 3: 
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Genomic DNA 
Reverse PCRpnmer、hME-lO tag 
(B) PCR Product + 
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( C ) hME Reaction ^ 
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Figure 2.3.2 Principles of Sequenom multiplex homogenous MassEXTEND 
(hME) assay. The hME assay is a simple and robust method for analysis of SNPs. 
(A) Genomic DNA is amplified using hME-10 tag primers. (B) Arctic shrimp 
alkaline phosphatase (SAP) was added to remove phosphate from the PCR 
products and residual amplification nucleotides. (C) The addition of a DNA 
polymerase along with a mixture of terminator nucleotides allows the extension 
of the hME primer through the polymorphic site and generates allele-specific 
extension products, each having a unique molecular mass. (D) The resultant 
masses of the extension products are then analyzed by MALDI-TOF mass 
spectrometry. Each addition of a nucleotide to the primer extension product 
increases the mass by 289-329 Daltons. The mass difference is easily resolved by 
MALDI-TOF which has the ability to detect differences as small as three Daltons. 
A genotype is assigned in real time. (Adopted and modified from Sequenom 
application notes) 
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2.3.4 Statistical analysis 
All statistical tests were performed by SPSS (version 15, Chicago, IL, USA). Data 
are represented in mean士SD or percentage whereas appropriate. 
In addition to intraplate concordance rate, genotype distributions were also 
checked by Hardy-Weinberg Equilibrium (HWE) with test in case and control 
separately. Single SNP association with type 2 diabetes was assessed by test in 
additive or dominant model (11 vs 12+22, where 2 is the minor allele) due to the 
relatively low minor allele frequencies in some SNPs. Logistic regression was also 
performed to adjust the association with age and sex. Odds ratio (OR) with 95% CI 
are presented. Quantitative traits including BMI, waist to hip ratio (WHR), FPG, 
HbAic, TG, TC, HDL-C and LDL-C were compared for SNPs under dominant 
model by Student's t-test and further adjust for age and sex with linear regression. 
For interaction between SNPs in PTGIS and PPARD, logistic regression including 
the main and interaction effects of the SNPs was performed to assess the 
association with type 2 diabetes with adjustment for age, sex and BMI. The SNP 
interaction effect on quantitative trait association was also assessed by linear 
regression adjusted for age, sex, B M I and diabetes status. 
Linkage disequilibrium (LD) statistics were calculated and visualized using 
Haploview (Barrett et al, 2005)(available at vvwvv.broacl.mit.edu/mpu/haploview). 
Power calculation was performed using STPLAN (available at 
biostatistics.mdanderson.org). A p <0.05 and <0.1 were considered statistically 
significant and a trend for association, respectively. 
59 
2.4 Results and Discussion 
2.4.1 Clinical characteristics of the study population 
In this study population, the type 2 diabetic subjects are a little younger than the 
non-diabetic control. The type 2 diabetic patients have significantly higher BMI, 
W H R , blood pressure, FPG, worse lipid profile (higher TG, T C and lower 
HDL-C) as compared to the control subjects (pO.OOl). Also, there are more 
diabetic subjects with M E S than the controls (Table 2.2.1). 
2.4.2 Genotyping and LD analysis 
Among the 12 SNPs selected, 2 SNPs (rs5580 and rs5583) could not be 
genotyped, 2 SNPs (rs575253 and rs6019877) were found to be non-polymorphic 
in our Hong Kong Chinese population. The genotypes of rs5580 and rs5583 
cannot be determined possibly because they are located in the promoter region 
which contains the V N T R repeats and GC-rich regions. This makes the PCR 
amplification of the flanking regions and binding of MassEXTEND primers 
difficult. For the remaining 6 SNPs in PTGIS and 2 SNPs in PPARD, they all had 
call rates higher than 98% and the average call rate was 99.6%. The concordance 
rate based on 52 blind duplicate samples for each SNP was 99.7%. All SNPs were 
distributed according to H W E in both cases and controls as assessed by i test {p 
>0.05). The high call rates, high concordance rate and genotyping distributions in 
H W E indicate that the samples and genotyping are in good quality. This study 
cohort has >80% power to detect case-control association with minor allele 
frequency >0.2 and O R of 1.5. 
For the genotyped SNPs, they have a coverage with Han Chinese HapMap SNPs 
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[Minor Allele Frequencies (MAF) > 0.05] of 54.84% and 60.61% in PTGIS and 
PPARD, respectively. LD analyses (Figure 2.4.1) showed that in PTGIS 
rs7267348, rs495146, rs6019876, rs5629, rs5600 have high r^  values and 
therefore they will have similar genotype distributions and are in the same LD 
block, while rs508757 is an independent block. For PPARD, rs6902123 and 
rs2016520 have a high D' but a low r^  value, which means that they are linked 
evolutionarily but they have different allelic distribution. 
(a) I I (b) n 
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Figure 2.4.1 Linkage disequilibrium (LD) analyses of the SNPs used in this 
study for (a) PTGIS and (b) PPARD. The number in the middle of the square 
shows the pairwise r^  value. Red colour indicates a D' = 1 and LOD ^ 2 while 
white colour means D' < 1 and LOD < 2. 
2.4.3 Association with type 2 diabetes and related metabolic traits 
2.4.3.1 Single SNP association with type 2 diabetes 
Table 2.4.1 shows the MAF frequencies of 6 SNPs in PTGIS and PPARD in our 
study cohort and in comparison with the HapMap data, and association results 
with type 2 diabetes in additive and dominant models. The genotyped SNPs have 
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similar M A F with those of HapMap except for rs2016520. It has a M A F of 〜9% 
higher than that from Han Chinese in HapMap. However, it should not affect the 
interpretation of the data as this SNP has a high call rate (99.84%) and is in H W E 
(p=l). The higher M A F may reflect the actual frequency in this study cohort. 
rs508757 in PTGIS showed a trend for association in additive and dominant 
models with the adjustment for age and sex (additive: adjusted OR=0.72, 95% 
CI=0.52-1.01, /7=0.054). Other SNPs showed similar allele frequencies in case 
and control. Therefore, these SNPs were not associated with type 2 diabetes in 
























































































































































































































































































































































































































































































































































































































































































































































































2.4.3.2 Single SNP association with metabolic traits 
The association of single SNP with the diabetes-related metabolic traits including 
BMI, SBP, DBP, FPG, HbAic, T G and cholesterol levels (TC, LDL-C and HDL-C) 
was assessed separately in diabetic and control groups in dominant model due to 
low M A F ofrs508757 and rs6902123 (Table 2.4.2 on page 67). In diabetic group, 
FPG level was significantly higher in carriers of TT homozygote of PPARD 
rs6902123 (TT: 9.00士3.43 vs CT+CC: 8.00士2.26，/7=0.016) but the association 
was lost (p=0.092) after adjustment for age and sex. 
In control group, homozygous A A of PPARD rs2016520 was associated with 
higher LDL-C level after adjustment for age and sex (AA: 3.09土0.85 vs A G + G G : ‘ 
2.92±0.80, p=0.044). Major genotypes of 4 SNPs (rs508757, rs7267348， 
rs495146, rs5600) in PTGIS showed a trend of relatively higher SBP (p<0.1). 
Moreover, the major genotypes of 3 SNPs in PTGIS (rs7267348, rs495146, and 
rs5629) showed a trend in higher W H R (p<OA) after adjustment. 
PPARD rs6902123 has been associated with glucose uptake and risk of 
conversion from IGT to type 2 diabetes. The TT genotype of rs6902123 had 
significantly lower whole body glucose uptake ( W B G U ) which was mainly due 
to lower skeletal muscle glucose uptake in healthy individuals (Vanttinen et al, 
2005). The lower W B G U of the TT genotype is consistent with the observation in 
this study that FPG was higher in TT carriers from the diabetic group. However, a 
study of the STOP-NIDDM trial showed that the female carriers of rs6902123-C 
had 2.7-fold increase in risk of conversion from IGT to type 2 diabetes 
(Andrulionyte et al., 2006). These seemingly paradoxal observations indicate that 
the role of PPARD rs6902123 in diabetes and glucose metabolism requires 
further elucidation. 
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PPAR5 has also been implicated in cholesterol metabolism. Treatment of 
macrophages, fibroblasts and intestinal cells with PPAR5-specific agonist 
(GW501516) promotes reverse cholesterol transport (Oliver et al., 2001). Also, 
GW501516 increases HDL-C and lowers LDL-C in obese rhesus monkeys (Oliver 
et al., 2001). Skogsberg et al. demonstrated that the carriers of homozygous G G of 
PPARD rs2016520 have higher LDL-C as compared to the homozygous A A 
carriers in healthy men of Northern European origin (Skogsberg et al, 2003), 
which is opposite to our findings. This may partly due to ethnic difference 
(Ikegami et al.’ 2006; Lyon et al., 2006). Nevertheless, it is interesting to note 
that PPARD rs2016520 can influence LDL-C level in both cohorts. Further studies 
are required to elucidate the molecular/cellular mechanisms underlying the 
association between rs2016520 and LDL-C metabolism. 
Several SNPs in PTGIS showed trends in association with SBP in the control 
subjects. Although they were not at significant level, they may provide further 
information for PTGIS gene polymorphisms in controlling blood pressure. PTGIS 
V N T R polymorphism in the promoter has been associated with higher SBP (Iwai 
et a!., 1999). In this study, the intronic SNPs also had mild association with SBP. 
More genotyping in a larger population may help substantiate the association of 
these intronic SNPs with SBP and the potential interaction between the V N T R 
and these intronic SNPs. Although rs7267348, rs495146 and rs5629 had a trend 
for association with W H R in the control subjects (p<0.1), the difference between 
the major and minor genotype groups was small (from 0.001 to 0.003). Thus, this 
association may not have strong physiological significance. 
The single SNP analyses in the PTGIS gene indicate that several minor alleles 
were associated with metabolic traits in the controls, but not the cases. One 
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possible explanation is that these SNPs might confer a degree of protection which 
is masked by the selection of a case population with early onset and presumably 
more severe disease. Therefore, a follow up study to propose would be to look 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.3.3 Gene-gene interaction on type 2 diabetes 
In order to explore potential gene-gene interaction, rs508757 in PTGIS which 
showed a trend for association with type 2 diabetes and rs20l6520 in PPARD 
which was associated with LDL-C level were assessed for SNP interaction for 
association with type 2 diabetes in a logistic regression model with adjustment of 
age, sex and BMI (Table 2.4.3). Although PTGIS rs508757 had some trend in 
association in type 2 diabetes, it did not further interact with PPARD rs2016520 
to increase the risk of type 2 diabetes. 
Table 2.4.3 Logistic regression results of pairwise SNP interaction for 
association with type 2 diabetes 
Adjusted OR 95% CI p value 
rs508757 0.641 0.361 - 1.139 0.129 
rs2016520 1.056 0.817— 1.366 0.675 
rs508757*rs2016520 1.295 0.600-2.797 0.510 
Age 0.980 0.967-0.993 0.002 
Sex 1.436 1.123- 1.837 0.004 
BMI 1.209 1.169- 1.252 <0.001 
Constant 0.014 - <0.001 
2.4.3.4 Gene-gene interaction on metabolic traits 
The interaction of PTGIS rs508757 and PPARD rs2016520 was also tested for 
diabetes-related metabolic traits in linear regression model in the total study 
population adjusting for age, sex, BMI and diabetic status (Table 2.4.4). They 
showed an interaction on FPG (p=0.016) but not on other metabolic traits. 
Furthermore, there was no interactive effect among PTGIS rs508757, PPARD 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The rationale for investigating the interaction between PTGIS and PPARD on the 
risk of type 2 diabetes and metabolic traits derived from the close functional 
relationship of the two genes. As mentioned in the introduction, PTGIS encodes 
the key enzyme in producing PGh which is important in vasodilation [6] and 
polymorphisms in PTGIS have been associated with hypertension (Iwai et al., 
1999). Besides being a vasodilating factor, recent studies demonstrated that PGI2 is 
also a potent activator of PPAR5 (Gupta et al, 2000; Lim et al., 2002; Lim et al, 
1999). PPARS is a powerful transcription factor which regulates lipid and 
glucose metabolism as well as energy homeostasis (Grimaldi, 2005; Barish et al, 
2006; Furnsinn et al, 2007). Activation of PPAR5 improves insulin sensitivity and 
lowers FPG in db/db mice and reduces hepatic glucose output by increasing 
glucose catabolism through the pentose phosphate shunt and utilization of glucose 
through activating fatty acid synthesis (Lee et al, 2006). In human primary 
skeletal myotubes, PPARS agonists increase glucose uptake possibly through 
activation of AMP-activated protein kinase (AMPK) pathway without altering the 
expression of GLUTl and GLUT4 (Kramer et al., 2005). And PPARD 
polymorphisms (rs6902123, rs2076l67 and rs 1053049) had been associated with 
whole body and skeletal muscle glucose uptake. Therefore, it is conceivable that 
the polymorphisms in the two genes may interact and confer risk to type 2 diabetes 
or modify metabolic traits. Although no variant in these two genes was found 
associated with FPG or HbAic in single SNP comparison, when rs508757 in 
PTGIS and rs2016520 in PPARD were subjected to pairwise SNP analysis, they 
showed a significant interactive effect on FPG and HbAic in the diabetic group. A 
similar trend for FPG was also observed in the control group. Such interaction is 
not significant in the control group (p=0.054) but may have a physiological 
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implication. Carriers of rs508757-G and A A homozygous of rs2016520 have 
relatively higher FPG level and these genotypes possibly predispose them to 
higher risks of diabetes or other high-glucose induced complications, such as 
endothelial dysfunction. It is important to note that SNPs are just markers of 
regions on the D N A and cannot, without verification, be given a causal role in the 
phenotype being studied. Therefore, the notion above remains hypothetical and 
must be established through direct experimentation. 
The lack of association with FPG at single SNP level emphasizes that for 
multi-factorial diseases, gene-gene interaction may be a more useful tool to detect 
disease- or phenotype-associated genes (Moore, 2003; Moore, 2005). In addition, 
PTGIS rs508757 is an intronic SNP and PPARD rs2016520 is located at the 5’ 
untranslated region of the gene. The fact that blood glucose level was influenced 
by the interaction of the two non-coding SNPs indicates the significance of gene 
regulatory regions as modifiers of metabolic traits. 
In the meta-analysis results of type 2 diabetes from Diabetes Genetics Replication 
and Meta-analysis Consortium (DIAGRAM) (Zeggini et al., 2008), rs508757 was 
not genotyped or imputed in the dataset while the other SNPs did not reach 
genome-wide significance threshold (p<5 x 10"^ ) (WTCCC, 2007; Hoggart et al, 
2008). This further confirms that the SNPs genotyped in this study are not 
associated with type 2 diabetes. However, it would be interesting to meta-analyze 
our data with the whole genome scan results of type 2 diabetes-related metabolic 
traits from Diabetes Genetics Initiative (DGI) when the data is available. 
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2.5 Limitation and improvement 
Although our study has sufficient power to detect association with strong genetic 
effect, the power to detect ORs around 1.2 as demonstrated by recent type 2 
diabetes genome-wide association studies (Sladek et al., 2007; Scott et al, 2007) 
was limited. Furthermore, the association results were not corrected for multiple 
testing and therefore more explorative. Given these limitations, future studies 
using larger cohorts are required to further substantiate the present findings. 
2.6 Conclusions 
The SNPs in PTGIS and PPARD genotyped in this study are not associated with 
type 2 diabetes in the Hong Kong Chinese population. However, PTGIS 
rs508757 and PPARD rs2016520 elicit a significant epistatic effect to influence 
blood glucose level. The association should be followed up with functional or 
molecular studies to resolve the possible underlying mechanisms. 
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Chapter 3: Functional Studies of Prostacyclin Synthase 
rs508757-A/G Intronic Polymorphism 
3.1 Introduction and research design 
From the association study results discussed in Chapter 2, the polymorphisms of 
PTGIS rs508757 and PPARD rs2016520 interacted to influence blood glucose 
level. These two polymorphisms should be demonstrated functionally active to 
further substantiate the genotype-phenotype association. The transcriptional 
activities of the PPARD rs2016520-A or -G allele have been previously studied in 
vitro (Skogsberg et al, 2003). The luciferase constructs driven by the proximal 
promoter and 5' untranslated region of PPARD from -731 to +310 (+1 denotes the 
transcriptional start site) including either allelic variant (A/G) were transfected 
into human monocytic U937 cells. The common A allele showed a lower 
luciferase signal which implied a lower transcriptional activity. And gel-shift 
assay showed that transcription factor Sp-1 bound specifically to the G allele 
rather than the A allele and increased the transcriptional activity of the G allele in 
SL2 cells which lack Sp-1. These two pieces of evidence suggest that the 
rs2016520-A carriers may have a lower PPAR5 expression and activity. However, 
the PTGIS rs508757-A/G polymorphism thus far has not been investigated and 
the following studies will be focused on this polymorphism with the attempt to 
prove its functional significance and explain the association study results. 
The rs508757 flanking sequence was analyzed with bioinformatics tools to gain 
clues to the function of the polymorphism. Two hypotheses were generated: 1) 
There is a novel gene present nearby; 2) The rs508757 flanking sequence serves 
as a regulatory element. These hypotheses were tested by molecular assays: 1) 
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The presence of a novel transcript was tested by RT-PCR; 2) The D N A structure 
of the rs508757 flanking sequence was resolved by circular dichroism; 3) The 
effect of rs508757 flanking sequence on promoter activity was tested with 
dual-luciferase reporter assay. 
In addition, transcription factor binding site prediction was performed for PTGIS 
rs508757 and PPARD rs2016520 to explore more functional roles of these two 
polymorphisms. 
3.2 Materials and methods 
3.2.1 Bioinformatics 
3.2.1.1 Cross-species alignment 
The cross-species alignment of PTGIS genomic sequences was obtained from the 
VISTA Browser (Frazer et al., 2004) (http://genome.lbl.gov/vista/index.shtrnl). 
VISTA is a comprehensive suite of programs and databases for comparative 
analysis of genomic sequences. VISTA servers allow users to submit and align 
their own sequences whereas the VISTA Browser provides pre-computed 
alignments of whole genome assemblies from different species. The nucleotide 
alignment of the PTGIS rs508757 flanking sequence was obtained from the 
Ensembl Genome Browser (http://www.ensembi.org/). 
3.2.1.2 BLAST search and open reading frame prediction 
The conserved sequence from the intron 6 of PTGIS (human chromosome 20: 
47572394-47570795) was submitted to the search for highly similar sequences in 
the expressed sequence tags (EST) database on National Centre for 
Biotechnology Information (NCBI) using the Basic Local Alignment Search Tool 
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Nucleotide (BLASTN) function nittp://blast.ncbi.nlm.nih.govA). 
Open reading frame (ORF) prediction of the conserved sequence was performed 
by O R F finder (http://vvw\v.ncbi.nlm.nih.^ ov/gorf/gorF.htmn. It is a graphical 
analysis tool which finds all open reading frames in a user's sequence or in a 
sequence already in the database. 
3.2.1.3 Transcription factor binding sites prediction 
The transcription factor binding sites in the flanking sequence of PTGIS 
rs508757 and PPARD rs2016520 were predicted by the M A T C H program 
(httD://vvvvw.izene-regulation.com/). M A T C H uses a library of mononucleotide 
weight matrices from TRANSFAC 6.0. 
3.2.2 PCR amplification from cDNA 
In order to test the presence of a novel transcript from the conserved region, two 
- primers were designed (BF: 5' T T C C T G C C C T C T C T C C T G A T 3”； BR: 5’ 
A T C C C A G T C C C C A C C C C T T 3，）to amplify the predicted ORF from several 
genomic D N A digested cDNAs (from WRL68, HepB3, HuH7, HepG2 and 
SaS02 cells) and human genomic D N A (Promega, Madison, WI, USA) as 
positive control using Taq D N A polymerase. cDNAs were gifts from Prof. 
Stephen Tsui of Department of Biochemistry, CUHK. The cycling condition was 
as follows: 
Step Temperature Time No. of cycle 
Initial denaturation 95°C 5 min 1 
Denaturation 95°C 30 s 
Annealing 55°C 30 s 35 
Extension 7 2 ^ ^ 
Final extension 72°C 10 min 1 
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After two rounds of PCR, the products having target size around 200bp were 
purified with gel extraction. The identities of the products were determined by 
DNA sequencing (service provided by Macrogen Inc., Seoul, Korea). 
3.2.3 Culture of mammalian cell 
3.2.3.1 Cell line 
The human aorta smooth muscle cell T/G H A - V S M C (VSMC) was purchased 
from American Type Culture Collection (Manassas, VA, USA). 
3.2.3.2 Medium and supplement 
High glucose Dulbecco's Modified Eagle's Medium ( D M E M ) containing 4500 
mg/1 D-glucose, 4 mmol/1 L-glutamine, 100 mg/1 sodium pyruvate and 4 mg/1 
pyridoxine HCl (Gibco B R L Life Technologies, Inc, Carlsbad, CA, USA) was 
prepared by dissolving powder in double distilled water and buffered with 3.7 g/1 
sodium bicarbonate (Sigma, St. Louis, M O , USA). The pH of the medium was 
adjusted to -7.3 and then filtered through 0.22 )im filter (Millipore, Billerica, 
Mass, USA) for sterilization. 
The supplement fetal bovine serum (FBS) and penicillin-streptomycin (P/S) were 
purchased from Invitrogen. FBS was added to the D M E M medium at a final 
concentration of 10% (v/v). The working concentration for P/S antibiotic mixture 
was 1% which contained 100 units/ml penicillin G sodium and 100 |ig/ml 
streptomycin. 
3.2.3.3 Cell culture wares 
100-mm cell culture dish, 6-well plate, 15-ml and 50-ml culture centrifuge tubes 
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were purchased from Greiner Bio-one (Frickenhausen, Germany). 
3.2.3.4 Cell culture conditions 
V S M C cells were maintained in high glucose D M E M medium (10% FBS and 
1% P/S) in a humidified incubator at 37°C with 5% CO2. Fresh medium was 
replaced every 2-3 days. When the cells reached 90% confluence, they were 
trypsinized and subcultured at 1:4 dilution. 
3.2.4 Construction of reporter vectors with rs508757 flanking sequence 
3.2.4.1 Cloning and vector preparation 
An intron 6 fragment from PTGIS (human chromosome 20: 47572511-47572001) 
containing rs508757 (47572378) was cloned by PGR using primers (sense, 5' 
T A A G G A T C C T T G C T T G A G C C C A G G A G T T T G A G A C 3'; anti-sense, 5, 
T A A G T C G A C C G C C C A G A G A A A A A T C C C A A G T C 3'; BamHI and Sail sites 
are underlined respectively) from commercial human genomic D N A (Promega, 
Madison, WI, USA). Following gel electrophoresis and purification, the BamHI 
and Sail digested fragment (containing the rs508757-A allele) was sub-cloned 
downstream of a firefly luciferase gene in pGL3-promoter vector (Promega). The 
identity of the clone (pGL3-A) was confirmed by D N A sequencing (service 
provided by Macrogen). 
3.2.4.2 Site-directed mutagenesis 
To introduce an A to G substitution at +45711, site-directed mutagenesis was 
performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA, USA). Briefly, the mutagenesis required two synthetic oligonucleotide 
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primers and the pGL3-A construct as template. The primers Ml: 5’ 
GGGGGTCAGGGGGACAGGGGG 3' and M2: 5' 
C C C C C T G T C C C C C T G A C C C C C 3’ (desired mutation underlined), each 
complementary to the opposite strands of the vector, were extended during 
temperature cycling by PfuUltra D N A polymerase. Incorporation of the 
oligonucleotide primers generated a mutated plasmid containing staggerd nicks. 
Following temperature cycling, the product was treated with DpnI. The Dpnl 
endonuclease (target sequence: 5'-Gm^ATC-3') is specific for methylated and 
hemimethylated D N A and was used to digest the parental pGL3-A D N A template 
and to select for mutation-containing synthesized DNA. The nicked vector D N A 
containing the desired mutation was then transformed into E. coli competent cells 
(DH5a). The pGL3 vector containing rs508757-G (pGL3-G) was isolated using 
Plasmid D N A extraction Miniprep System (Viogene, Taipei, Taiwan). The 
identity of the clone was confirmed by D N A sequencing (service provided by 
Macrogen). 
3.2.5 Dual-luciferase reporter assay 
3.2.5.1 Transfection ofVSMC 
Transfection grade plasmids (pGL3-promoter, pGL3-A and -G) were prepared 
using Ultrapure Plasmid D N A Midiprep system (Viogene). The day before 
transfection, V S M C of passages 4-5 were seeded at 1 x 1 a t each well of 6-well 
plates and cultured to achieve 〜90o/o confluence at the time of transfection. 
Transfection was performed using the Lipofectamine 2000 reagent following the 
manufacturer's instruction with optimizations (Invitrogen, Carlsbad, CA, USA). 
For each well, 4 |a.g of the luciferase construct and 4 ng of Renilla luciferase 
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reporter, pRL-CMV vector (Promega) were mixed in 250 |il of plain D M E M 
without serum or antibiotics while 12 |il of Lipofectamine 2000 was also mixed 
with 250 jil plain D M E M . After 5 minutes of incubation at room temperature, the 
D M E M diluted plasmid D N A and Lipofectamine 2000 were mixed gently and 
incubated for 20 minutes at room temperature to generate the 
DNA-Lipofectamine complexes. During the incubation, the growth medium in 
the 6-well plates was aspirated and replaced with 1 ml plain D M E M . Finally, 
SOOfxl DNA-Lipofectamine complexes were added to each well. Five hours 
post-transfection, plain medium was replaced with the growth medium 
(containing 10% FBS and 1% P/S). Cells were incubated at 37°C in 5% CO2 for 
24 hours prior to cell lysis. 
3.2.5.2 Cell lysis and luminescence measurement 
Cells were harvested 24 hours after transfection. First, growth medium was 
removed and cells were washed with Phosphate Buffered Saline. Then, cells were 
lyzed with Ix passive lysis buffer provided with the dual-luciferase assay kit 
(promega) for 30 min with shaking. The cell lysates were treated with one 
freeze-thaw cycle to ensure complete lysis. After that, cell lysates were 
centrifuged at 12000 rpm in a microcentrifuge (Eppendorf, Hamburg, Germany) 
for 4 min at 4°C to pellet cell debris. 
Firefly luciferase activity was measured by adding 50 of LARII substrate to 50 
}il of cell lysate, and then 50 |il S & G reagent was added to the sample to quench 
the firefly luciferase activity as well as initiate the Renilla luciferase activity. The 
luminescence measurement was performed using the 2101 En Vision multilabel 
plate reader (PerkinElmer, Waltham, M A , USA) in 96-well format. The relative 
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luciferase activity was calculated by normalizing the firefly luciferase activity to 
the activity of the Ren ilia internal control which minimized experimental 
variability caused by differences in cell viability or transfection efficiency. 
3.2.6 Circular Dichroism 
3.2.6.1 Introduction to DNA quardruplex structure and circular dichroism 
3.2.6.1.1 DNA quardruplex 
In cellular environment, D N A mostly adopts a double-helix structure in which 
adenine (A) pairs with thymine (T) while guanine (G) pairs with cytosine (C) 
under the Watson-Crick model. However, sequence motifs containing stretches of 
tandem of Gs can also form four-stranded structures called G-quardruplex (Sen et 
ai, 1990; Paramasivan et al, 2007). The stacked tetrads were held through 
mutually hydrogen-bonded guanines. G-quardruplex motifs occur throughout the 
human genome, raising the possibility of physiological functions (Shirude et al., 
2007). The mostly studied G-quardruplex forming sequence is the telemoric 
overhang. Molecules that bind to quadruplex D N A have been shown to inhibit 
telomerase and to be selectively toxic to tumor cells (Shammas et al., 2004) 
which may be due to disruption of telomere structure. 
Quardruplex motifs are also present in nontelomeric parts of the genome, where 
quadruplex formation must compete with the D N A duplex. A well-studied case is 
the DNasel nuclease hypersensitive region within promoter of a proto-oncogene 
c-MYC. This region contains a sequence to form a G-quardruplex which has been 
shown to repress the expression of c-MYC. Furthermore, the quadurplex D N A 
may play a role in recombination (Hardin et al., 1991). 
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3.2.6.1.2 Circular dichroism 
Circular dichroism (CD) is a form of spectroscopy based on the differential 
absorption of left- and right-handed circularly polarized light. It can be used to 
determine the structure of macro-molecules including proteins and D N A and has 
been used to examine the structure of quardruplex D N A s (Paramasivan et al., 
2007). With the C D spectra of a reference set of D N A s of known structures 
(Figure 3.2.1), it is possible to determine the structure of a D N A molecule 
through comparison with the reference spectra. 
(A) d(GGTTGGTGTGGTTGG) (B) d(GGGGTTTTGGGG) 
:tvxAJ lW\ A 
： 衝 
E I I I I I I I I I 1 i ' I I I I I 1 I I I I I [ I 
^ 220 260 300 nm 220 260 300 nm 
3 
\ (C) d(TGGGGT) (D) d(TAGGGUTAGGGT) 
= ： 娜 
—I”II~I~I~~II~I~~II~I~ HI~I~I""II~I"""III~I~I 
220 260 300 nm 220 260 300 nm 
Figure 3.2.1 CD spectra of the four reference quadruplex DNAs. The 
structures of each of the D N A s are shown. (A) Chair-type antiparallel structure in 
100 mmol/l KCl. (B) Basket type antiparallel structure in 140 mmol/1 KCl. (C) 
Four-stranded parallel structure in 100 mmol/1 KCl. (D) External loop parallel 
structure in 5 mmol/1 NaCl and 100 mmol/1 KCl. The experiment details will be 
described in the following section. (Adopted from Paramasivan et al., 2007) 
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3.2.6.2 Circular dichroism measurement 
3.2.6.2.1 DNA samples 
D N A s were purchased from Invitrogen and supplied as HPLC purified samples. 
Oligonucleotides used are listed in Table 3.2.1. 
Table 3.2.1 Oligonucleotides used in CD experiment. Polymorphic sites are 
underlined. The positive control oligonucleotide contains human telomeric repeat 
motif d ( G G G T T A G G G T T A G G G T T A G G G ) which can form an intramolecular 
quadruplex structure (Ying et al., 2003). It is used as a reference to distinguish 
inter-/intra- molecular quadruplex structures. 
Name Sequences 
Positive d ( G G G T T A G G G T T A G G G T T A G G G ) 
rs508757-A d ( G G G G G G T C A G G A G G A C A G G G G G ) 
rs508757-G d ( G G G G G G T C A G G G G G A C A G G G G G ) 
3.2.6.2.2 CD spectroscopy 
C D spectroscopy was carried out as previously described (Paramasivan et al, 
2007). The D N A samples were then prepared at a concentration of 1x10"^  mol/l in 
a buffer containing 0.1 mmol/l EDTA at pH 7.0 and 100 mmol/l KCl. The D N A 
samples were heated to 372 K, cooled slowly to room temperature and incubated 
at 298 K before obtaining the C D spectra. The C D spectra were recorded using a 
Jasco J-810 spectropolarimeter equipped with a temperature controlled cell 
holder at 298 K and the path length was 0.2 cm. Data was obtained from 350 to 
200 nm at 0.1 nm wavelength intervals. Each spectrum corresponded to an 
average of three scans from which the buffer background was subtracted. 
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3.2.7 Statistical analysis 
Dual-luciferase reporter results were presented as mean士S.E.M. Differences in 
transcriptional activity between D N A constructs were evaluated by one-way 
A N O V A with SPSS (version 15, Chicago, IL, USA). A p value of <0.05 was 
considered statistically significant. 
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3.3 Results and Discussion 
3.3.1 Cross-species alignment 
Comparison of D N A sequences from different species is the conventional method 
for identifying functional elements in genomes (Frazer et al, 2004). This study 
first used cross-species alignment to obtain information on the function of PTGIS 
rs508757. Figure 2.3.1a shows the genomic sequence alignment of PTGIS from 
human, mouse (Mus musculus), dog {Canis familiaris) and cow (Bos taurus). 
There is a peak at intron 6 of PTGIS which has over 70% cross-species 
conservation. The conserved region peaked at 47571576 on chromosome 20 and 
the shoulder spreads about 1.6kb which covers rs508757 (nucleotide alignment 
can be found in appendix). This highly conserved sequence indicated important 
biological function. 
The nucleotide alignment of the rs508757 flanking sequence was revealed in the 
Ensembl genome browser (Figure 3.3.1). It shows that the flanking sequence is 
conserved among the four species (human, mouse, dog and cow). Also, there are 




Dog TC;TrrrAAG(5G:’:|AGG:裤"lAGGSGG^ XGACAGICACAGAAACACmCAGGCTGATT-TAAAIGTGGATAT&rAGGAI 
Human CATTTCJSC'GGGT^AGGRGG^llAGGGGG^AfiASAfiTCAAGGAAACATMAaUGSTGAniTAC-AIGATGATAIGIAGASI 
Mouse :AITT;:A---G;^;|AGGG<y5|>jAGGAAG{rrGAG-GTC:AGGAAACASSC:CAG--TG GCTG -GGAI 
Figure 3.3.1 Cross-species nucleotide alignment of rs508757 flanking 
sequence. The conserved region is highlighted in blue shadows. The position of 
rs508757 is indicated by arrow. The two conserved A G G G G G repeats are 
highlighted in red boxes. (Adopted from Ensembl genome browser at 
http://www.ensei'nbl .org/) 
Based on the cross-species alignment result, three hypotheses were generated: 1) 
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The conserved 1.6kb sequence at intron 6 of PTGIS encodes for a novel 
transcript; 2) The rs508757 flanking sequence contains a regulatory element that 
affects the transcription of PTGIS and 3) The 22nt around rs508757 (5， 
G G G G G G T C A G G R G G A C A G G G G G 3’’ where R is the polymorphic site) is 
G-rich and form quardruplex structure, thus affecting transcription. 
3.3.2 BLAST search and ORF prediction 
To gain further information on whether the 1.6kb conserved intronic region of 
PTGIS contains another gene, the sequence (human chromosome 20: 
47572394-47570795) was blasted against the EST database in NCBI. A bovine 
muscle c D N A clone, DY208889, was fished out. There are 290nt overlapping 
between the 1.6kb conserved region and the bovine cDNA clone. Thus, it is 
possible that the conserved region in intron 6 of human PTGIS can be expressed 
into a transcript. A pair of primers (BF and BR, sequences as shown in section 
3.2.2) was designed to amplify this overlapping region from cDNAs generated 
from m R N A . 
If the conserved sequence is expressed, it may be further translated into protein. 
Therefore, an O R F prediction was also performed for the 1.6kb sequence to seek 
for possible protein coding regions. The longest ORF predicted was 366nt and in 
-1 frame. Also, the ORF overlaps with the bovine cDNA clone. Figure 3.3.2 
provides a summary for the BLAST search results and ORF prediction. 
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Search against EST database in NCBI: 
51 I I I I I I m ' ^ 
Length 
PTGIS intron ,：級 
conserved sequence ^ ^ ^ ^ ^ ^ ― r 
t n 
rs508757 Blast against EST database in NCBI 
Bovine muscle cDNA | | | H | H H | | 544bp I • overlap between 
clone (DY208889) ^ ^ ^ ^ P PTGIS and bo^ne 
ORF prediction: cDNAdone 
5' umiiiiiiijiiiiiiiiiiiiiiiiiiiiiiiiii 3， 
ORF < I (-1 frame) 
• Longest ORF predicted: 366nt 
• Overlap with Bovine cDNA clone 
Figure 3.3.2 Summary diagram on BLAST search and ORF prediction 
results of the conserved region of PTGIS intron 6. The locations of primers for 
P C R are shown in purple. 
3.3.3 PCR results on testing the presence of a new transcript 
P C R was performed using BF and B R primers using several cDNAs and human 
genomic D N A (Figure 3.3.3). All templates except the bone cancer cell line 
SaS02 could get a band ~200bp. The target bands were excised and amplified in 
2nd round of P C R to collect enough products for sequencing. However， 
sequencing results showed that only the product from genomic D N A contained 
the desired sequence. Therefore, the predicted transcript was not present in the 
tested cell lines. 
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Figure 3.3.3 PCR results on testing the presence of a new transcript. The 
target product size is indicated by arrow (~200bp). 
3.3.4 Effect of rs508757 flanking sequence on SV40 promoter activity 
One possible mechanism of PTGIS rs508757 and PPARD rs2016520 influence 
blood glucose level is that they may affect the transcriptional activity of their 
corresponding genes. The allelic effect of PPARD rs2016520 on transcriptional 
activity has been demonstrated (Skogsberg et al., 2003). To investigate whether 
the spanning region of rs508757 contains an intronic regulatory element, luciferase 
constructs containing rs508757-A or G allelic forms were cloned down-stream of 
the SV40 promoter and transfected into V S M C cells. Figure 3.3.4，shows that the 
A allelic form of the fragment enhanced transcriptional activity of the SV40 
promoter (/7<0.001) by about 60% whereas the G counterpart of the fragment did 
not have a significantly effect. Also, when compared to the G allelic form, the A 
allele had 25% increase on SV40 promoter activity (p=0.002). 
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Figure 3.3.4 Effect of rs508757 on SV40 luciferase activity. The activity of 
control vector was set to 100%. The A allele showed a 60% increase on SV40 
promoter activity when compared to the vector control (p<0.001) while G allele 
did not have a significant effect. Also, when compared to G allelic form, A allele 
had 25% increase on SV40 promoter activity (p=0.002). Data shown are 
mean士SEM of three independent experiments in triplicate set up (n=9). 
Transient transfection assays performed by Skogsberg et al showed a lower 
transcription activity for the A allele of PPARD rs2016520, suggesting a lower 
PPAR5 activity (Skogsberg et al.’ 2003). Our association study results lead us to 
examine the potential functional significance of PTGIS rs508757 in order to 
further understand the mechanisms underlying the interactive effect of PTGIS and 
PPARD polymorphisms on blood glucose level. Luciferase assay showed that the 
common A allelic form of this putative regulatory sequence significantly enhanced 
the activity of SV40 promoter as compared to its G allelic form. These results 
imply that rs508757-A carriers have higher PTGIS transcriptional activity. 
The results of PTGIS and PPARD transcription studies obtained so far indicate that 
the G allelic form of rs508757 and the A allelic form of rs2016520 are associated 
with lowered transcriptional activities of their respective genes. If the \n vitro 
results reflect the expression of these genes in vivo, a lowered expression of PTGIS 
would be expected to lead to reduced PGI2 production and thus compromises 
PPAR5 activation which may be further down-regulated by the lowered expression 
of PPARD associated with rs2016520-A allele (Skogsberg et al., 2003). Consistent 
with this notion, the rs508757 G and rs2016520 A A homozygous carriers showed 
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the highest FPG or HbAic in this study cohort. Based on the same notion, the 
rs508757 A A homozygous and rs2016520 G carriers should have the lowest FPG 
or HbAic. This however, is not represented in our data, suggesting the complexity 
of the control of glucose homeostasis (Kruger et al, 2006) and indicating that 
other variables should be considered to fully explain the physiological outcome of 
the interaction between the two genes. 
I performed further analysis on the D N A structure and transcription factor 
binding sites prediction with the attempt to obtain more information on the 
allele-specific activity of rs508757. 
3.3.5 Circular dichroism experiment on rs508757 flanking sequence 
The flanking sequence of rs508757 is rich in guanine nucleotides (5' 
G G G G G G T C A G G R G G A C A G G G G G 3,，where R is the A/G polymorphic site). 
From previous studies, we suspected that this SNP flanking sequence may form an 
intra-molecular quadruplex structure (Paramasivan et al., 2007) in an 
allelic-dependent manner and cause changes in transcription regulation 
(Siddiqui-Jain et al., 2002). After obtaining and comparing C D spectra of 22nt 
flanking sequences to the reference spectra (Figure 3.3.5), however, the flanking 
nucleotides were not able to form intramolecular quadruplexes. Moreover, the A 
and G allelic forms did not show structural difference. Therefore, the difference 
of transcription activity incurred by the rs508757 polymorphism should involve 
mechanisms other than formation of D N A multiplex structures, such as 








Figure 3.3.5 Circular Dichroism (CD) spectra of positive control, rs508757-A 
and -G oligonucleotides in 100 mmol/l KCl. Positive control has the spectrum 
of an intramolecular quardruplex structure while A and G show similar 
intermolecular quardruplex spectra. 
100 mmol/l KCl buffer was used because this concentration of K+ is in the 
physiological range (Hardin et al,, 1991) and was used in the reference spectra 
for the intra- and intermolecular quadruplex (Paramasivan et al., 2007). Although 
this 22nt sequence cannot form an intramolecular structure which may not have 
significant effect on transcription activity, the formation of intermolecular 
structure may have another biological implication. Studies proposed that the 
genomic region favourable of intermolecular quadruplex formation could act as 
an initial point of chromosomal alignment pairing in preparation for homologous 
recombination events (Hardin et al., 1991). This may partly explain the low 
linkage disequilibrium ofrs508757 to other HapMap SNPs of PTGIS. 
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3.3.6 DNA slipping model 
Besides D N A quardruplex formation, another possible mechanism to explain the 
allele-specific activity of PTGIS rs508757 is the D N A slipping model. Figure 
3.3.6 shows the details of the model. In the rs508757-A form, the G G G G G G 
upstream of the polymorphic site may slide and pairs with C C C C C downstream. 
This forms a hairpin structure and allows interaction with transcription factor 
(structure 1-1). In the rs508757-G form, a similar hairpin structure may also 
appear (structure 1-2). However, the G G G G G sequence flanking the polymorphic 
site (underlined) may compete with the G G G G G G sequence and form another 
D N A structure (structure 2). As structure 2 competes with structure 1-2, there is 
less chance to form the hairpin structure for interaction with transcription factors. 
Thus, the above mechanism may explain the observation that the rs508757-A 
form has a higher transcription activity in the luciferase assay. The mechanism 
proposed for this thesis is a novel one but transcription regulation due to 
alternative secondary structure formation of the promoter region have been well 
established in bacteria (Waye et al., 1986). 
( A ) GGG6GGTCAGGAGGACAGG666CAGAGA6 ( G ) GGGGGGTCAGGGGGACAGGGGGCAGAGAG 
CCCCCCAGTCCTCCTGTCCCCCGTCTCTC CCCCCCAGTCCTCCTGTCCCCCGTCTCTC 
( 1 - 1 ) A (1-2) G (2) 
i 1 I 
GGGGGGCAGAGAG GGGGGGCAGAGAG TCAGGGGGCAGAGAG 
CCCCCGTCTCTC CCCCCGTCTCTC CCCCCGTCTCTC 
Figure 3.3.6 DNA slipping model The polymorphic site is underlined. In the 
rs508757-A form, the G G G G G G (orange) upstream of the polymorphic site may 
slide and pairs with C C C C C (orange) downstream. This forms a hairpin structure 
and allows interaction with transcription factor (structure 1-1). While in the 
rs508757-G form, a similar hairpin structure may also appear (structure 1-2). 
However, the G G G G G (red) sequence flanking the polymorphic site (underlined) 
may compete with the G G G G G G (orange) sequence and form another D N A 
structure (structure 2). 
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3.3.7 Transcription factor binding site prediction 
It is possible that the two alleles of an SNP alter the preference of interaction 
with transcription factors and thus lead to different transcriptional activity. Figure 
3.3.7a and b show the predicted transcription factor binding sites for PTGIS 
rs508757-A and -G flanking sequences (121nt, with polymorphism at position 
61 nt), respectively. The transcription factors are indicated by transcription factor 
ID followed by the score of matrix match in parentheses with the arrows 
indicating the binding position and orientation. The score of matrix match 
indicates the similarity and identity of the input sequence to the transcription 
factor consensus binding site. The transcription factors with binding sites 
spanning the PTGIS rs508757 polymorphic site are highlighted in red and 
summarized in Table 3.3.1. Transcription factors c-Ets-1 and v-MAF were 
predicted to bind A allelic sequence, ARP-1 binds G allelic sequence, while AP-1, 
ER and PAX4 bind both allelic sequences. Some of these factors are involved in 
glucose or insulin metabolism, i.e., v-MAF and PAX4. v-MAF controls p cell 
gene expression such as G L U T 2 and Glucagon-Like Peptide 1 Receptor (GLPIR) 
whereas PAX4 is involved in p and 5 cells differentiation. The prediction shows 
that the rs508757 flanking sequence is able to interact with transcription factors 
which may be implicated in type 2 diabetes. Further studies on allele specific 
transcription factors, c-Ets-1, v-MAF and ARP-1 may explain the underlying 
mechanisms for different transcriptional activity of rs508757. 
Although PPARD rs2016520 has been shown to interact with Sp-1 to affect 
transcription (Skogsberg et al., 2003), further transcription factor binding site 
prediction can promote the understanding on the regulation of rs2016520 on gene 
expression since Sp-1 may not be the only transcription factor acting on 
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rs2016520. Figure 3.3.8a and b show the predicted transcription factor binding 
sites for the C and T allele (which correspond to G and A allele in dbSNP allele 
coding respectively). The transcription factor information is summarized in Table 
3.3.2, OCT-1 and c-Ets-1 may be good candidates for future characterization as 
they co-operate with Sp-1 to activate gene transcription, however, N F k B has 
been ruled out by gel shift assay (Skogsberg et al., 2003). 
Very interestingly, the spanning sequences of PTGIS rs508757 and PPARD 
rs2016520 are complementary (rs508757, 5' A G G A C A 3' and rs2016520, 5’ 
T C C T G T 3，，polymorphic sites are underlined) and both sequences are able to 
interact with transcription factors c-Ets-1 and PAX4 by prediction. Thus, it is 
possible that the transcriptional activities of PTGIS and PPARD are co-regulated 
by common transcription factors (i.e. c-Ets-1, PAX4 and Spl) which have been 
implicated in diabetes. C-Ets-1 was associated with type 1 diabetes in a Japanese 
population (Aparicio et al.’ 1990) whereas PAX4 is important for p cell 
differentiation (Liew et al.’ 2008). In the Asian population, PAX4 had been 
associated with first phase C-peptide secretion in Japanese and a younger age at 
diagnosis in Thai subjects with type 2 diabetes (Tokuyama et ai, 2006; 
Plengvidhya et al, 2007). The activity of Spl is controlled by insulin and is 
inhibited in diabetic condition (Majumdar et al, 2004). These observations also 
support the interactive effect of PTGIS rs508757 and PPARD rs2016520 on blood 
glucose found in the association study (discussed in Chapter 2). Further 
association and molecular studies on the interactions between these transcription 
factors and PTGIS!PPARD will elucidate the transcriptional regulations involved 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.3.1 Summary of transcription factors predicted to act on PTGIS 
rs508757. (A) Transcription factor information from TRANSFAC 7.0 database. (B) 
Transcription factors were grouped according to allelic preference. 
m 
Factor ID Full name Known function 
V$AP1_Q4 Activating Protein 1 Composed of two subunits: Jun or 
Fos peptide; down-modulated by 
glucocorticoids through direct 
interaction with glucocorticoid 
receptor (GR) 
VSARPl Ol Apolipoprotein Al May act as an activator or 
Regulatory Protein 1 repressor; repressor of ApoAI and 
ApoCIIl genes 
V$CETS1P54_01 v-ets erythroblastosis Proto-oncogene; expresses in 
virus E26 oncogene lymphoid tissue, brain and vascular 
homolog 1 (c-Ets-1) endothelial cells; act synergistically 
with AP-1, NF-kappaB, Spl and 
ATF; associate with type 1 diabetes 
in Japanese 
V$ER_Q6 Estrogen Receptor a Regulate gene expression in 
(ERa) response to estrogen; associate with 
type 2 diabetes or end-stage renal 
disease in African-American and 
with type 2 diabetes in Chinese 
women 
V$PAX4_01 Paired Box Gene 4 Differentiation of endocrine 
progenitors to beta and delta cells; 
in mouse it binds to islet hormone 
promoters such as glucagon, insulin 
and somatostatin and can act 
competitively to Pax-6 as a 
repressor 
V S V M A F Ol v-maf Viral oncogene; with several 
musculopaponeurotic human homologues, like M A F A ; 
fibrosarcoma oncogene M A F A controls beta cell gene 
homolog A (v-Maf) expression, such as G L U T 2 and 
Glucagon-Like Peptide 1 Receptor 
(GLPIR) 
(B) = 
Binding site Transcription Factors 
A-allele specific c-Ets-1, v-Maf 
G-allele specific ARP -1 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.3.2 Summary of transcription factors predicted to act on PPARD 
rs2016520. (A) Transcription factor information from TRANSFAC 7.0 database. (B) 
Transcription factors were grouped according to allelic preference. 
m 
Factor ID Full name Known function 
V$CETS1P54—01 v-ets erythroblastosis Proto-oncogene; express in 
virus E26 oncogene lymphoid tissue, brain and 
homolog 1 (c-Ets-1) vascular endothelial cells; act 
synergistically with AP-1, 
NF-kappaB, Spl and ATF; 
associate with type 1 diabetes in 
Japanese 
VSCOMPl Ol Myogenin factor 4 Induce myogenesis; recognize 
( M Y O G ) helix-loop-helix binding sites 
V$CREL—01 v-rel reticuloendotheliosis Bind with N F K B 1 or N F K B 2 to 
viral oncogene homolog form heterodimer; NF-kB is 
A, NFKB3, p65 (c-Rel) activated in short lasting 
hyperglycemia or in type 1 
diabetes patients 
V$ELK1_02 ELKl Interact with serum response 
factor and form a ternary 
complex; control smooth muscle 
gene expression 
VSIKl Ol Ikaros family zinc finger Play a critical role in development 
1 of the lymphocyte lineage 
V$MYOGNF1_01 Neurofibromin I (NF-1) A negative regulator of the ras 
signal transduction pathway 
V S N F K A P P A B O1 Nuclear Factor of kappa A transcriptional regulator in 
B complex (N F k B ) immune cell development and 
V $ N F K B Q6 inflammation; activated in 
一 diabetic nephropathy 
V$OCTl_Q6 Octamer-binding factor Transcriptional activator; 
co-operate with Spl and Oct-1 
associated protein (OAP40); 
ubiquitously expressed; interact 
with other TFs such as ERa and 
Apl 
V$PAX4一01 Paired Box Gene 4 Differentiation of endocrine 
progenitors to beta and delta cells; 
in mouse it binds to islet hormone 
promoters such as glucagon, 
insulin and somatostatin and can 




Binding site Transcription Factors 
C-allele specific N F k B , N F 1 
T-allele specific c-Ets-1, IKl 
Both alleles M Y O G , C-Rel, ELK 1，OCTl, Pax4 
3.4 Limitation and improvement 
The present study used only the viml promoter SV40 to test the effect of 
rs508757 flanking sequence on gene transcription, it will better resemble the 
biological context when human PTGIS promoter is used. Moreover, the V N T R 
repeats in the PTGIS promoter, which regulates gene expression, may have an 
interactive effect with rs508757 in controlling transcriptional activity. 
The transcription factor binding site prediction has a high false-positive rate, so 
the candidate transcription factor should be further verified through biological 
assays. For examples, overexpression of the candidate transcription factor in 
culturing cells can identify the effect of the factor while gel shift assays can be 
performed to confirm the physical interaction between the transcription factor 
and the predicted binding site. 
3.5 Conclusions 
The results from the present study supported the hypothesis that the rs508757 
flanking sequence contains an intronic regulatory element eliciting allele-specific 
effect on gene transcription. The results also substantiate the association results 
from genetic study by providing function significance for the polymorphism. 
More molecular studies on transcription factors will promote the understanding 
of the regulation of PTGIS and PPARD gene expression. 
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Chapter 4: General Discussion, Conclusion and Future Perspectives 
4.1 General discussion 
In this project, the results from the case-control study support the first hypothesis 
and provide the first piece of evidence that the genetic polymorphisms in PTGIS 
and PPARD interact to modify blood glucose level in the Hong Kong Chinese 
population. 
Previous studies of PTGIS gene polymorphisms mainly focused on vascular 
diseases, including hypertension, myocardial- and cerebral-infarction (Iwai et al., 
1999; Nakayama et al, 2000; Nakayama et al, 2002) as initially PGIS were 
found to be expressed in smooth muscle and endothelial tissues and PGI2 is a 
vasodilator and inhibitor of platelet aggregation through acting on PGI2 receptor 
(Wu et al., 2005). Later expression studies showed that PGIS was also expressed 
in non-vascular tissues such as adipocytes, embryo, lung and colorectal cancer 
while the action of PGI2 can be further targeted on PPARS. Together with the 
type 2 diabetes linkage signal on chromosome 20 (Klupa et al., 2000), these 
evidences raised my interest in studying the potential association of PTGIS gene 
polymorphisms with type 2 diabetes and metabolic traits. Moreover, it would be 
interesting to test whether there is gene-gene interaction between PTGIS and a 
type 2 diabetes susceptibility gene PPARD based on their close biochemical 
relationship - endogenous PGI2 is an activator of PPAR5. 
The association study showed that although at individual SNP level, there were 
no tested polymorphisms found associated with type 2 diabetes, PTGIS rs508757 
and PPARD rs2016520 interacted to modify blood glucose level in the study 
population. By using bioinformatics and luciferase assay, PTGIS rs508757 
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flanking sequence was identified as an intronic enhancer and rs508757-G allele 
had a lower transcriptional activity compared with the A allele. Previous studies 
showed that PPARD rs20I6520-A allele had a lower transcriptional activity than 
the G allele (Skogsberg et al., 2003). Based on the activity of these two intronic 
SNPs, a proposed model for the association on blood glucose was made (Figure 
4.1.1). A lowered expression of PTGIS associated with rs508757-G would be 
expected to lead to reduced PGI2 production and thus compromises PPARS 
activation which may be further down-regulated by the lowered expression of 
PPARD associated with rs2016520-A allele. The interactive effects of the two 
SNPs may cause changes in the downstream metabolic gene expression which in 
turn alter blood glucose level. Activation of PPARS with agonist GW501516 has 
been shown to increase the expression of glucose-6-phosphate and fatty acid 
synthase (FAS) in liver (Lee et al., 2006). The upregulation of these two enzymes 
can increase glucose consumption and reduce hepatic glucose production. 
Glucose-6-phosphate utilizes glucose through glycolysis or pentose-phosphate 
shunt while FAS promotes fatty acid synthesis which may consume more glucose. 
Moreover, GW501516 stimulates glucose uptake in 3T3-L1 mouse adipocytes and 
primary human myotubes. The effect on primary human muscle cells is possibly 
through the upregulation of A M P K (Kramer et al.’ 2005). From the effects of 
synthetic PPARS agonist on glucose metabolism, it is speculated that the lowered 
expression of PGIS and PPAR5 caused by rs508757-G and rs2016520-A alleles 
respectively may lead to higher blood glucose level which was observed in this 
cohort (Figure 2.4.2). The carriers in the control group also had a similar trend, so 
it is possible that rs508757-G and rs2016520-A can predispose a healthy 
individual to higher blood glucose level. 
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Figure 4.1.1 Proposed model for the interactive effect of PTGIS rs508757 and 
PPARD rs2016520 on blood glucose level. PGIS produces PGI2 which is an 
endogenous activator of PPARS. Transfection studies showed that PTGIS rs508757 
affects transcriptional activity in an allele-specific manner. Previously studies also 
demonstrated that PPARD rs2016520 can regulate PPARD transcription. Therefore, 
the protein expression level of PGIS and PPARS may be influenced by rs508757 and 
rs2016520, respectively. The changes in PGIS and PPARS activities will affect 
downstream metabolic gene expression and eventually modify blood glucose level. 
The activation of PPARS with agonist GW501516 has been shown to reduce hepatic 
glucose production (Lee et al., 2006). It is thus conceivable that PTGIS and PPARD 
may interact to affect hepatic glucose production. The interaction between PTGIS 
rs508757 and PPARD rs2016520 on fasting blood glucose only (and not D M per se) 
raises the possibility that the major target of this interaction is hepatic glucose 
production. This possible interaction can be further integrated with central nervous 
system control of hepatic glucose production. Insulin action in the hypothalamus is 
essential for maintaining hepatic insulin sensitivity and normal glucose production 
by the liver (Porte et al, 2005). The hypothalamus also senses and responds to 
nutrient and intracellular energy status and thus regulating food intake and hepatic 
insulin sensitivity (Figure. 4.1.2) (Schwartz et al.’ 2005). Therefore, PTGIS, PPARD, 
insulin and hypothalamus may cooperate systemically to establish control of hepatic 
no 
glucose production. 
Nutrient-related . Circulating 
signals (e.g. FFA) ^^ nulrlents 
Glucose production M 
' ^ y i ^ . i a o l ， a v a i l a b i l i t y 
^ ^ ^ Energy ba lance 
intake expenditure Body fat mass 
• ‘ Adiposity-related 4 . 念. 
signals (leptin. insulin) ^ " " " — , 
Figure 4.1.2 Model depicting the control of energy homeostasis and hepatic 
glucose metabolism by adiposity- and nutrient-related signals. Neuronal systems 
sense and respond to input from hormones such as insulin and leptin that are secreted 
in proportion to body energy stores and from the metabolism of circulating nutrients 
(such as glucose and free fatty acids, FFAs). In response to this input, adaptive 
changes occur in energy intake, energy expenditure, and hepatic glucose production. 
(Adopted from Schwartz et al., 2005) 
Another possible reason for the interactive effect is only found on blood glucose, 
but not on the risk of type 2 diabetes is that type 2 diabetes is a heterogenous 
disease in which multiple pathways, multiple genes and multiple environmental 
factors are involved. The epistatic effect of PTGIS rs508757 and PPARD 
rs2016520 may only contribute to the elevation in blood glucose while the 
initiation and progression of type 2 diabetes require other metabolic dysfunctions 
such as insulin resistance, P-cell failure and lowered energy expenditure. 
Inclusion of polymorphisms in other diabetes-related genes like transcription 
factors c-Ets-1, PAX4 and Spl in the interaction model may better predict the 
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Since high glucose environment and diabetic condition cause tyrosine nitration 
which inactivates PGIS (Zou, 2007) whereas low activity of PGIS may increase 
blood glucose level through co-operating with PPARS, a vicious cycle between 
high blood glucose and inactivation of PGIS may be formed. In addition to blood 
glucose level, inactivation of PGIS can also lead to vascular endothelial 
dysfunction and further complicate the disease condition. The results from this 
study suggest the PGIS-PPAR5 pathway can be a candidate target to lower blood 
glucose and ameliorate endothelial dysfunction. 
Figure 4.1.3 integrates previously reported results with major findings in this 
project. PTGIS gene polymorphisms were associated with vascular diseases 
including higher systolic blood pressure (SBP) and risk of myocardial infarction. 
In this project, four SNPs (rs508757, rs7267348, rs6019876 and rs5600) had a 
trend for association with SBP. This further supports the involvement of PTGIS 
in vascular diseases. Moreover, transfection study showed that rs508757-A has a 
higher transcription activity. In PPARD, previously, rs6902123 was associated 
with the risk of conversion from IGT to type 2 diabetes. Rs2016520 was 
associated with LDL-C and its G allele was demonstrated to have a higher 
transcription activity than the A allele. In this project, rs2016520 was also 
associated with LDL-C in the control group. Furthermore, through transcription 
factor binding site prediction, PTGIS and PPARD may be co-regulated by c-Ets-1, 
PAX4 and Spl. 
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Figure 4.1.3 Integrated view of previously reported results and major 
findings in this project. In PTGIS, previously, the V N T R polymorphism in the 
promoter region was associated with systolic blood pressure (SBP) and risk of 
hypertension while the C C genotype of rs5629 was associated with myocardial 
infarction. In this project, four SNPs (rs508757, rs7267348, rs6019876 and 
rs5600) had a trend for association with SBP. Transfection study showed that 
rs508757 elicits an allele-specific effect on transcription activity. In PPARD, 
previously, rs6902123 was associated with the risk of conversion from impaired 
glucose tolerance (IGT) to type 2 diabetes (T2D). rs2016520 was associated with 
LDL-C and its G allele was demonstrated to have a higher transcription activity 
than the A allele. In this project, rs2016520 was also associated with LDL-C in 
the control group. Through transcription factor binding site prediction, PTGIS 
and PPARD may be co-regulated by c-Ets-1, PAX4 and Spl. 
In summary, through genotyping PTGIS and PPARD SNPs in a Hong Kong 
Chinese type 2 diabetes cohort, the SNPs in PTGIS and PPARD were found to 
have an interactive effect on blood glucose level. Cross-species genomic 
sequence alignment revealed possible functions of PTGIS rs508757 flanking 
sequence including generating new ORF, formation of quardruplex structure and 
acting as a regulatory element. In vitro assay demonstrated PTGIS rs508757 
regulates promoter activity in an allele-specific manner. Transcription factor 
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binding site predictions showed that transcription of PTGIS and PPARD may be 
co-regulated by c-Ets-1, PAX4 and Spl which had been implicated in diabetes. 
Further association and molecular studies will promote the understanding on the 
cooperation of these genes in diabetes (Figure 4.1.4). 
PAX4, c-Ets-l & Spl PAX4. c-Ets-1 & Spl 
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Figure 4.1.4 Summary of major findings in this project. Through genotyping 
PTGIS and PPARD SNPs in a Hong Kong Chinese type 2 diabetes cohort, the 
SNPs in PTGIS and PPARD were found to have an interactive effect on blood 
glucose level. Cross-species genomic sequence alignment revealed possible 
functions of PTGIS rs508757 flanking sequence including generating new ORF, 
formation of quardruplex structure and acting as a regulatory element. In vitro 
assay demonstrated PTGIS rs508757 regulates promoter activity in an 
allele-specific manner. Transcription factor (TF) binding site predictions showed 
that transcription of PTGIS and PPARD may be co-regulated by c-Ets-1, PAX4 
and Spl which had been implicated in diabetes. Further association and 
molecular studies will promote the understanding on the cooperation of these 
genes in diabetes. 
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4.2 Future perspectives 
4.2.1 Association study on type 2 diabetes and molecular interaction between 
transcription factors, PTGIS and PPARD 
Based on computer prediction and experimental results from previous studies, 
PTGIS rs508757 and PPARD rs2016520 are speculated to interact with the 
common transcription factors, PAX4, c-Ets-1 and Spl. These transcription factors 
have been implicated in diabetes. Statistical testing of the interaction among the 
polymorphisms of these transcription factor genes and PTGIS/PPARD may better 
predict the phenotypic outcomes in diabetes. Molecular studies should also be 
performed to substantiate the physical interaction of these transcription factors 
with PTGIS rs508757 and PPARD rs2016520 and investigate the effect of these 
transcription factors on the expression of the two genes. 
4.2.2 Association with diabetic nephropathy 
PGIS knock-out mice developed vascular disorders with the thickening of 
vascular walls and interstitial fibrosis, especially in the kidneys (Yokoyama et al, 
2002). Their kidneys developed progressive morphological abnormalities which 
were accompanied by atrophy, surface irregularity, fibrosis, cyst, arterial sclerosis, 
and hypertrophy of vessel walls. Importantly, these phenotypes have not been 
reported in PGb-receptor deficient mice which indicate the possible involvement 
of another PGI2 receptor such as PPAR5 in the development of renal 
abnormalities. Together with the association of PTGIS and PPARD gene 
polymorphisms on blood glucose, it would be interesting to explore the potential 
genetic and molecular association of these two genes on diabetic nephropathy. 
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4.2.3 Study tissue or cell type specific actions of PGIS and PPARS 
The tissue specific actions of PGIS and PPAR5 are not fully understood. 
Functions of PGI2 were mainly known in vascular tissue and embryo but PGIS is 
also expressed in adipocyte, cardiac myocytes and cancer cells. The unknown 
action of PGI2 in these tissues requires further investigation. Likewise, PPAR5 is 
expressed in brain, liver, (3 cell, V S M C s and endothelium. Each of which has 
connections to the components of the metabolic syndrome, yet its functions in 
each of these tissues and cell types remained unexplored. More researches using 
tissue or cell type specific targeted knock-out or overexpression techniques are 
required to understand the tissue specific effects in both normal and disease 
conditions. 
4.3 Conclusions to my project 
In conclusion, this is the first study showing that PTGIS rs508757 interacts with 
PPARD rs2016520 to modify blood glucose level and elicits allele-specific effect 
on gene transcription. Further molecular studies on rs508757-spanning region will 
elucidate the function of PTGIS and its relationship with PPARD as well as the 
cooperation of these two genes in the control of metabolic traits relevant to type 2 
diabetes. 
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